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Abstract (word count: 167/200) 
 
The global burden of disease caused by respiratory syncytial virus (RSV) is 
increasingly recognized, not only in infants, but also in older adults. Advances in 
knowledge of the structural biology of the RSV surface fusion (F) glycoprotein have 
revolutionized RSV vaccine development by providing a new target for preventive 
interventions. The RSV vaccine landscape has rapidly expanded to include 19 
vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting 
the urgency of reducing this global health problem and hence the prioritization of 
RSV vaccine development. The candidates include mAbs and vaccines using four 
approaches: (1) particle-based, (2) live-attenuated/chimeric, (3) subunit, (4) vector-
based. Late phase RSV vaccine trial failures highlight gaps in knowledge regarding 
immunologic protection and provide lessons for future development. In this review 
we highlight promising new approaches to RSV vaccine design and provide a 
comprehensive overview of RSV vaccine candidates and mAbs currently in clinical 
development to prevent one of the most common and severe infectious diseases in 
young children and older adults worldwide.
 6 
Search strategy and selection criteria 1 
References for this review were identified through a search of PubMed for clinical 2 
trials with “syncytial” in the title published after January 1, 2013 with no language 3 
restrictions, through April 3, 2018. We did not intend to do a systematic review of 4 
the literature. No inclusion or exclusion criteria were used. Instead, we selected 5 
articles that were most relevant to the subheadings used in this review. The PATH 6 
RSV vaccine and mAb Snapshot was used as a reference to identify all vaccine and 7 
mAb candidates in clinical trials. ClinicalTrials.gov as well as the WHO vaccine 8 
pipeline tracker for RSV were used to identify all relevant trials for these vaccine 9 
candidates and mAbs. Additional data was collected during the RSV Vaccines for the 10 
World Conference on November 29- December 1, 2017 and through pharmaceutical 11 
websites for the respective vaccine and mAb candidates.  12 
 7 
Introduction 13 
Respiratory syncytial virus (RSV) acute lower respiratory infection (ALRI) has 14 
gained recognition as a global health problem with a high burden of disease and no 15 
vaccine licensed for prevention. In children under 5 years, it is estimated that 33.1 16 
million episodes of ALRI, 3.2 million hospital admissions and as many as 118,200 17 
deaths were attributable to RSV worldwide in 2015(1) [Figure 1]. Although often 18 
characterized as a pediatric disease, RSV in adults represents a significant health 19 
burden. Mortality attributable to RSV in adults ≥65 years of age is estimated to be 20 
7.2 per 100,000 person years(2) and 8% of RSV ARLI among older hospitalized 21 
adults was reported to result in death (3) in the United States(US). The. RSV vaccine 22 
candidates aim to protect at least three target populations that are at risk for severe 23 
RSV disease: (1) young infants through passive immunization, (2) older infants and 24 
young children through active immunization, and (3) older adults.  25 
Development of effective RSV vaccines and monoclonal antibodies (mAbs) 26 
presents both opportunities and challenges. First, concerns of enhanced respiratory 27 
disease (ERD) following vaccination with the formalin-inactivated RSV (FI-RSV) 28 
vaccine in the 1960s have complicated the design and testing of RSV vaccines(4). 29 
Current vaccine candidates, especially those designed for RSV naïve infants and 30 
children, must demonstrate safety by avoiding these immunologic hallmarks of ERD. 31 
Second, an absolute correlate of protection against a clinically relevant RSV infection 32 
remains elusive, although cell-mediated immunity(5), mucosal IgA(6) and potent 33 
neutralizing antibodies(7) have been associated with decreased disease severity.  34 
Recently, three phase IIb/III trials (two vaccine trials in older adults(8,9) and 35 
one mAb trial in infants(10)) failed to meet clinical endpoints. In addition to 36 
possible inadequacies in trial design and implementation, the failure of these 37 
candidates demonstrates the continued gaps in knowledge regarding immunologic 38 
mechanisms of protection in the different target populations.  Another challenge to 39 
RSV vaccine design is the lack of consensus regarding clinical endpoints though 40 
attempts have been made to define these for RSV prevention trials(11–13). 41 
Furthermore, these endpoints may differ according to the target population. Finally, 42 
a consideration in RSV vaccine development is the limited protection conferred by 43 
immune responses elicited by natural RSV infection. Natural immunity provides 44 
only transient protection against subsequent infection and re-infection occurs 45 
frequently(14) though the most severe RSV disease is usually observed during the 46 
primary infection. Disease in older children and healthy younger adults is typically 47 
mild. Monoclonal antibodies circumvent the problem of transient immunity to RSV 48 
and an immature immune response to vaccination in young infants at risk of severe 49 
disease. An ideal RSV vaccine candidate should prevent severe disease in at risk 50 
populations. Certain vaccines might also lessen person-to-person transmission and 51 
thereby provide secondary benefits in those who cannot benefit directly from 52 
vaccination(15).  53 
 Despite these obstacles, there are several opportunities for RSV vaccine and 54 
mAb development. First, RSV disease burden has received increasing attention from 55 
international stakeholders such as the World Health Organization (WHO)(16) and 56 
the Bill & Melinda Gates Foundation based on better estimates of RSV-associated 57 
mortality worldwide(17). Second, the discovery and stabilization of the prefusion 58 
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(pre-F) conformation of the RSV F protein provided a new target for vaccines and 59 
mAbs(18,19) as pre-F specific antibodies may be more potent than postfusion (post-60 
F) antibodies in protecting against RSV ALRI. Third, pharmaceutical companies have 61 
recognized the urgent unmet need of RSV prevention and prioritized the 62 
development of RSV vaccines and mAbs.  63 
In 2015, a review of RSV prevention and therapeutic strategies was 64 
conducted which demonstrated that 10 vaccines were in clinical development(20). 65 
An update of that review is necessary in light of the recent failures and new 66 
candidates in the last few years.  In this review, we show that only 50% (5/10) of 67 
candidates from 2015 are currently continuing in clinical trials and 14 additional 68 
new candidates have entered clinical trials [Figure 2]. In the context of RSV as an 69 
increasingly recognized global health problem, these rapid changes and expansion 70 
show the prioritization of RSV vaccine and mAb development.  71 
  72 
 9 
Methods 73 
A data collection template was designed for all vaccines in clinical development 74 
according to the PATH RSV vaccine and mAb Snapshot (updated November 2017 75 
(21)) [Supplementary Table 1]. Gaps in knowledge were identified by searching 76 
PubMed, clinical trial registries, WHO, European Medicines Agency (EMA) and 77 
pharmaceutical websites for each vaccine candidate, with no language restrictions, 78 
through April 3, 2018 (NM, ACL, NH, IR, EP, JS). We did not intend to do a systematic 79 
review of the literature. No inclusion or exclusion criteria were used. Instead, 80 
articles were selected based on relevance to the subheadings used in this review as 81 
well as each vaccine candidate or mAb in clinical development. Furthermore, data 82 
for this review were systematically collected using a data collection template 83 
[Supplemental Table 1] at the RSV Vaccines for the World conference organized by 84 
the Respiratory Syncytial Virus Network (ReSViNET) from November 29 - 85 
December 1, 2017 in Malaga, Spain. The goal of this meeting was to share scientific 86 
data and expertise on RSV vaccine development, and to connect stakeholders 87 
involved in RSV research. During the meeting information was collected (NM, ACL, 88 
NH, IR, EP, JS) from scientific presentations, posters and personal communications. 89 
 We included all vaccine candidates and mAbs in clinical development 90 
according to the PATH RSV vaccine and mAb Snapshot. Vaccines were divided into 91 
four major groups: particle-based, vector-based, live-attenuated/chimeric and 92 
subunit vaccines. Immunoprophylaxis with mAbs was included as a fifth category. 93 
 94 
RSV Vaccine History 95 
RSV vaccine development started shortly after the first identification of the virus in 96 
humans in 1957(22). However, ERD upon natural RSV infection after vaccination 97 
with a formalin-inactivated RSV (FI-RSV) candidate in a series of trials in the 1960s 98 
severely hindered inactivated virus and subunit vaccine development for many 99 
years. In the youngest age group, 20 of 31 of RSV naïve infants were infected with 100 
community-acquired wild-type RSV during the next RSV season and 16 (80%) 101 
required hospitalization including two deaths(4) in whom ERD was documented. 102 
Decades of research have revealed that priming with FI-RSV vaccine triggered a 103 
strong but non-neutralizing antibody response(23), followed by a T-helper 2 (Th2) 104 
skewed immunologic response(24) which led to ERD upon natural RSV infection. 105 
Other aspects of the immune response implicated in ERD include distinct subsets of 106 
CD4 T-cells(25) and memory CD8 T-cells(26). The failure to mount a protective 107 
cytotoxic T-lymphocyte (CTL) response was coupled with excess lung eosinophilia 108 
and neutrophilia, monocytic infiltration, and immune complex deposition in the 109 
lungs(27).  110 
Nevertheless, work continued on development and human testing of live-111 
attenuated RSV vaccine candidates. In the following 60 years, only two products 112 
were licensed for prevention of RSV. The first product was RSV intravenous 113 
immunoglobulin (RSV-IVIG), a polyclonal immunoglobulin preparation with high 114 
titers of anti-RSV neutralizing activity that was approved in the US and Canada and 115 
discontinued after 2003. RSV-IVIG was replaced by the second approved product 116 
palivizumab, a humanized mAb directed against the RSV F glycoprotein(28,29). 117 
Since its initial approval in 1998, palivizumab remains the only licensed preventive 118 
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intervention against RSV after demonstrating a reduction of 39% to almost 80% 119 
reduction of RSV hospitalizations in preterm infants < 35 weeks gestational age with 120 
and without chronic lung disease respectively(29). Palivizumab has an excellent 121 
safety profile and is indicated for the prevention of severe RSV ALRI in children 122 
born prematurely, with congenital heart disease, for with chronic lung disease(30).  123 
Motavizumab, a higher affinity variant of palivizumab, was developed in 124 
early 2000 but was discontinued in 2010(31). In a non-inferiority head-to-head 125 
comparative trial motavizumab recipients had a slightly higher frequency of mild 126 
skin reactions following administration when compared to palivizumab(32). 127 
However, in a placebo-controlled trial, motavizumab was highly efficacious against 128 
inpatient and outpatient RSV LRI in healthy term American Indian infants (33). 129 
Nevertheless, without evidence of superiority compared to palivizumab, for 130 
protection from RSV-related hospitalization, evidence of slightly higher side effects, 131 
and no plan for dose reduction or cost-saving, the product did not attain regulatory 132 
approval(34,35).  133 
With respect to vaccines for active immunization, many approaches targeted 134 
for RSV naïve children were evaluated preclinically over the years. Live-attenuated 135 
vaccine candidates were considered safe for clinical evaluation in these children 136 
because these vaccines are not expected to cause ERD(36). Over the past 40 years, 137 
several biologically derived live-attenuated vaccine candidates with attenuating 138 
temperature sensitivity or cold-passage mutations were evaluated clinically, 139 
including in the pediatric population, but the appropriate balance of attenuation and 140 
immunogenicity, suitable for RSV-naive children and infants, remained elusive. After 141 
reverse genetics techniques became available in the 1990s, it became possible to 142 
design vaccines with the appropriate level of attenuation, but with increased 143 
immunogenicity(37). While pediatric live-attenuated RSV vaccine candidates were 144 
under continued evaluation since the 1970s there were relatively few trials of RSV 145 
subunit vaccines conducted before 2000, with the exception of the purified F protein 146 
(PFP) vaccines(38,39), and an RSV fusion (F) attachment (G), and matrix (M) 147 
subunit vaccine(40).  148 
Over the past 10 years development of preventive interventions for RSV has 149 
rapidly expanded. Currently, 19 vaccine candidates and mAbs for different target 150 
populations are in clinical trials, and many more are in preclinical development(21).  151 
 152 
Lessons from the vaccine and mAb graveyard 153 
While vaccine development has accelerated, there have been three recent late-phase 154 
vaccine and mAb trial failures. It is important to distil lessons learned from these 155 
results to inform future vaccine development.  156 
1. A phase III double-blind, placebo-controlled trial (NURSERY) evaluating 157 
REGN2222 (suptavumab), a mAb against antigenic site V on the RSV pre-F 158 
protein(41) was conducted at 250 sites in 19 countries. REGN2222 was 159 
administered once or twice during the respiratory season to 1,149 healthy 160 
preterm infants < 6 months of age with a gestational age ≤35 weeks who were 161 
not eligible to receive palivizumab prophylaxis. The trial did not meet its 162 
primary efficacy endpoint to prevent medically-attended RSV infections 163 
through day 150 of life(42). REGN2222 was accelerated from phase I to phase 164 
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III due to promising results and the US Food and Drug Administration (FDA) 165 
granted Fast Track designation in October 2015. A speculation for this failure 166 
may be inadequate dosing schedule in regard to the antibody half-life. 167 
Ultimately, the basis for failing to meet the primary clinical endpoint is not 168 
known, as analyses of this late-stage failure have not yet been made public. 169 
2. The second candidate that failed to meet the predefined study endpoint in 170 
phase III clinical trials was the RSV F nanoparticle vaccine candidate for older 171 
adults, a candidate based on aggregates of full-length post-F. The results of the 172 
preceding phase II showed modest efficacy(43) and promising 173 
immunogenicity measures, as determined by rise in geometric mean titer for 174 
IgG antibodies against the F protein and palivizumab competing antibodies 175 
(PCA), in the phase II trial(44). In the phase III trial, 11,850 subjects ≥60 years 176 
of age were enrolled in 60 US sites in a double-blind placebo-controlled trial 177 
(RESOLVE) over a single season starting November 2015 with 182 days 178 
follow-up for the efficacy outcome. The trial was granted fast track designation 179 
by the FDA in 2016. (45). However, the vaccine candidate failed to show 180 
efficacy against RSV moderate–severe lower respiratory tract disease (ms-181 
LRTD) in phase III results(9). Compared to the previous season, RSV acute 182 
respiratory disease (RSV-ARD) and ms-LRTD attack rates were lower than 183 
expected in the 2015 – 2016 season (RSV-ARD: 2.0% versus 4.9% and RSV-184 
msLRTD 0.4% versus 1.8% during the vaccine and previous season respectively). 185 
The vaccine manufacturer speculates that the difference in vaccine efficacy 186 
observed may in part be due to this lower attack rate as well as high pre-187 
existing immunity in the study population(43). Another proposed explanation 188 
for failure of this vaccine candidate is that the quantity of the immune 189 
response to vaccination may not represent effective immunity. For example, 190 
PCA titers may not correspond to effective immunity as non-neutralizing 191 
antibodies can also bind the palivizumab binding site and can interfere with 192 
the binding of neutralizing antibodies(46). In a post-hoc subgroup analysis, the 193 
vaccine candidate showed efficacy against hospitalizations for all-cause 194 
chronic obstructive pulmonary disease (COPD) exacerbations(43). Upon 195 
further analysis of the phase III results, there was a non-statistically significant 196 
trend towards higher RSV microneutralization titers in adults without RSV-197 
ARD when compared to adults with RSV-ARD, but this difference was not 198 
statistically significant. One conclusion that can be drawn from this trial is that 199 
late-phase clinical research for RSV vaccine candidates should include 200 
evaluation across more than one RSV season.  201 
3. Development of the MEDI-7510 vaccine candidate, a subunit vaccine candidate 202 
for older adults, was discontinued after a phase IIb trial in North America, 203 
Europe, South Africa, and Chile. The vaccine candidate was evaluated in 1900 204 
adults ≥60 years and the study failed to meet its primary objective, efficacy 205 
against RSV-associated respiratory illness between 14 days post vaccination 206 
throughout the end of the surveillance period, approximately 7 months. MEDI-207 
7510 was a subunit vaccine using soluble (unaggregated) postfusion (post-F) 208 
conformation of the F protein with a TLR4 agonist adjuvant. The vaccine 209 
candidate showed safety and immunogenicity with increased B and T cell 210 
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responses in the vaccine compared to the placebo group in a phase I clinical 211 
trial(47) after safety and improved immunogenicity with an adjuvant was 212 
demonstrated in a first-in-human trial(48). The incidence of RSV-associated 213 
respiratory illness as diagnosed by PCR was 1.7% and 1.6% in the vaccine and 214 
placebo groups respectively, for a vaccine efficacy (VE) of -7.1(47). No efficacy 215 
was found in secondary subset analyses. On day 29, 93% of vaccinees had an 216 
anti-F IgG antibody seroresponse and there was a 4.6 geometric mean fold rise 217 
in anti-F IgG titer at the end of the RSV season in vaccine recipients compared 218 
to the placebo group(47). One proposed explanation for the negative results 219 
may be that the choice of a post-F antigen induced antibodies without 220 
appropriate epitope specificity(49). Upon further analysis, other proposed 221 
explanations include a low incidence of laboratory-confirmed RSV in the study 222 
population, or selection of the study population, which included high-risk and 223 
low-risk older adults. Considerations for the future include selection of an 224 
older study population at higher risk of RSV infection. 225 
 226 
Vaccine antigens 227 
Vaccine antigens included in RSV vaccine candidates are diverse. The majority of 228 
vaccines in clinical trials (11/18) use the F protein, a class I viral fusion protein, as 229 
an antigenic target. The RSV F protein is highly conserved and facilitates viral fusion 230 
with host cells. Understanding the structural differences between pre-F and post-F 231 
conformations, as well as stabilization of the pre-F soluble forms, has resulted in 232 
advances in vaccine antigen design(19,50). Current vaccine candidates use pre-F 233 
and post-F as vaccine antigens [Table 1]. Of note, the predominant conformation 234 
displayed on the FI-RSV vaccine candidate was the post-F conformation(51). It 235 
remains unclear as to whether there is a trigger for the pre-F to post-F 236 
conformational change, but it does occur spontaneously, making it difficult to ensure 237 
that a wild-type F vaccine antigen maintains a pre-F conformation. However, 238 
stabilizing mutations have been identified that can preserve the pre-F-specific 239 
epitopes(50,52). The antigenicity of some stabilized pre-F constructs has not been 240 
rigorously investigated, and it remains an open question as to whether certain 241 
stabilizing mutations affect the conformation of antibody binding sites Assays to 242 
assess antigen conformation are needed. Likewise there is no consensus on cellular 243 
receptors that determine viral tropism(53).  244 
 Other less frequent vaccine antigens, used alone or in combination with other 245 
antigens, include the RSV envelope associated glycoproteins G (1/18) and small 246 
hydrophobic (SH) protein (1/18) as well as internal proteins: nucleocapsid (N) 247 
(3/18), M (1/18), and M2-1 (1/18). Besides the F protein, the G protein is the only 248 
other target for neutralizing antibodies on the viral surface. The G protein is most 249 
important for viral attachment and is less frequently utilized as a vaccine antigen 250 
due to high variability across RSV strains(54), and limited knowledge of its surface 251 
structure(55). The G protein exists as an oligomer on the surface of RSV particles 252 
and as a monomer when secreted from infected cells in soluble form(56). There is 253 
evidence that the soluble form of the G protein can act as a decoy that helps the 254 
virus evade the antibody response(57). Another possible vaccine target, the SH 255 
protein, is not well understood, but data suggest that it plays a role in viral 256 
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replication in vivo(53) and inflammasome activation(58). The SH protein contains a 257 
transmembrane and extracellular domains(59); the latter has been used as a 258 
vaccine antigen(60). Internal proteins are particularly relevant to induce T cell-259 
mediated immunity(55). As such, three non-membrane RSV proteins have been 260 
included in RSV vaccine design. The N protein is the major nucleocapsid protein that 261 
encapsidates the RNA genome of the virus(61). The M2-1 and M2-2 proteins are 262 
specific to RSV and other Pneumoviridae. M2-1 is essential for viral transcription 263 
(62), and M2-2 deletion is utilized in live vaccine candidates for viral attenuation. 264 
Finally, the M protein is a membrane-associated protein that gives virions their 265 
filamentous shape(63,64). In summary, different viral proteins are being employed 266 
as antigens in RSV vaccine design. Viral surface glycoproteins such as F and G are 267 
known to induce antibodies with differing neutralization capacity. The SH protein 268 
may be important for induction of antibody dependent cell-mediated cytotoxicity 269 
(ADCC), whereas non-membrane proteins are especially important to induce a 270 
robust T-cell response(55). 271 
 272 
Target populations 273 
RSV prophylactic interventions are designed to protect at least two populations 274 
most vulnerable to severe RSV disease: RSV-naïve young infants and children, and 275 
older adults, although other high-risk populations are important to consider. It is 276 
estimated that 45% of hospital admissions and in-hospital deaths due to RSV-ALRI 277 
occur in infants younger than 6 months of age(1), an age at which vaccines are 278 
generally less immunogenic. Older adults and adults with chronic cardiopulmonary 279 
conditions have emerged as an important target for RSV prevention due to an 280 
increased understanding of RSV burden in this population. An overview of all RSV 281 
vaccine candidates per target population is shown in Table 2. 282 
Maternal vaccination is utilized to provide passive immunity to young infants 283 
by boosting maternal vaccine-specific antibody titers that are actively transferred 284 
through the placenta, thereby extending the period of protection conferred by 285 
maternal antibodies. Historically, epidemiologic studies have demonstrated an 286 
association between higher maternal RSV antibody concentrations and protection 287 
from ALRI in infants(65). Passive transfer of antibodies to infants has been shown to 288 
be protective against severe RSV infection through the administration of high-titer 289 
polyclonal and monoclonal antibodies (RSV-IVIG and palivizumab) (28,29). The 290 
duration of protection of maternal vaccination is defined by the antibody half-life. 291 
Administration of mAbs is an alternative form of passive vaccination that can 292 
circumvent this hurdle due to extended antibody half-life through Fc alterations(66).  293 
The proof-of-principle of maternal vaccination as a tool to prevent infant disease 294 
has been demonstrated by the effective near-elimination of maternal and neonatal 295 
tetanus worldwide through tetanus toxoid vaccination in pregnancy(67).  Maternal 296 
vaccination may also play a role in preventing RSV infection in pregnant women and 297 
adverse birth outcomes, however data on the burden of RSV disease in pregnant 298 
women and the effect of RSV infection during pregnancy on the fetus is limited(68–299 
71)  300 
 Premature infants, a population at high risk for severe RSV disease, may be 301 
insufficiently protected by maternal vaccination given that the majority of IgG 302 
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transport occurs after 32 weeks gestational age(72). Globally 10% of children are 303 
born preterm(73). The burden is especially relevant in low and middle-income 304 
countries (LMICs) as more than 60% of preterm birth occurs in Sub-Saharan Africa 305 
and South Asia(74). Thus, a maternal vaccination strategy may not be sufficient to 306 
protect the high-risk preterm population if administered during the third trimester 307 
of pregnancy. Tetanus-diphtheria-acellular pertussis (Tdap) immunization in the 308 
second trimester is associated with higher cord-blood antibody titers as compared 309 
to third trimester immunization(75). A strategy of earlier vaccination could be 310 
considered for maternal RSV immunization to maximize protection for preterm 311 
infants. Other populations in which impaired transplacental antibody transfer may 312 
limit protection by maternal vaccination include infants of mothers with chronic 313 
infection, hypergammaglobulinaemia, malaria, and HIV infection(76). The ratio of 314 
transplacental antibody transfer and antibody decay kinetics are currently 315 
considered the main parameters to assess protection conferred via maternal 316 
vaccination. However, protection may also be mediated by breast milk antibodies 317 
transferred postnatally.  318 
 A combined strategy that utilizes passive immunization to protect young 319 
infants, via maternal vaccination or mAbs, followed by pediatric active 320 
immunization may be effective to prevent severe RSV infection in young 321 
children(77). The combined strategy is estimated to avert at least twice as many 322 
admissions per 100 births and four times as many in-hospital deaths per 1000 323 
births than maternal vaccination alone(77). This strategy will be particularly 324 
relevant to prevent morbidity and mortality in children with comorbidities who are 325 
at risk of severe RSV disease at older ages(78,79). A similar maternal and pediatric 326 
combined passive and active immunization strategy is currently employed for 327 
pertussis and influenza vaccination(76).  328 
 Although RSV is frequently considered a pediatric pathogen, it is important 329 
to consider the older adult population with regard to prevention of severe RSV 330 
disease. RSV has been identified as an important disease in older and high-risk 331 
adults, with a disease burden similar to that of influenza(3). It is estimated that RSV 332 
accounts for 10,000 – 14,000 deaths annually in adults over the age of 65 years in 333 
the US(2,3). In addition, older adults with comorbidities such as underlying heart or 334 
lung disease are at elevated risk of severe RSV disease; 4-10% of high-risk adults 335 
will develop acute RSV infection annually(3). 336 
 337 
Immunologic endpoints 338 
Antibodies are thought to be the key players in limiting RSV ALRI as evidenced by 339 
proven protection in immunoprophylaxis trials in children (28,29,33). Recent 340 
evidence from experimental human infection in adults shows a protective role for 341 
nasal RSV-specific IgA against RSV infection(6), underscoring the importance of 342 
mucosal immunity. A limited ability to generate memory IgA responses after RSV 343 
infection may be in part responsible for incomplete immunity and subsequent RSV 344 
re-infection. Antibodies directed against different antigenic sites of the F protein 345 
display different neutralization capacities with the most neutralization-sensitive 346 
epitopes exclusive to the pre-F conformation. Antibodies with specificity for 347 
antigenic sites Ø and V show high neutralizing activity and are exclusive to the pre-F 348 
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conformation(41,80). Antigenic site Ø is located at the apex of the pre-F 349 
conformation, the most variable region of the highly conserved F protein(19). 350 
Antibodies against antigenic site III prefer the pre-F conformation and exhibit high 351 
neutralizing activity(81). Antibodies directed against site II and IV, present on both 352 
pre-F and post-F, exhibit medium to high neutralization potency(80,82). Finally, 353 
antibodies against antigenic site I, present primarily on post-F, show weak or no 354 
neutralization. Escape mutants of these antigenic sites have been identified, but 355 
global RSV genetic data are needed to assess the molecular heterogeneity of RSV 356 
and the subsequent susceptibility or resistance to mAbs targeting RSV among 357 
circulating viruses.  358 
 The mechanisms of protection may differ according to vaccine type, and 359 
therefore, many different immunologic assays are employed in clinical trials. 360 
Neutralizing activity of serum is a frequent immunologic endpoint of vaccine trials. 361 
A measure of functional antibody response can be elucidated by the ratio of fold-362 
increase in RSV-binding antibodies to fold-increase in RSV-neutralizing antibodies 363 
(ELISA-to-neutralization response ratio). A ratio of <1 may be an important 364 
correlate of protection(83). Furthermore, rather than a definitive protective 365 
threshold for antibodies, fold-rise in antibody titer may be a relevant correlate of 366 
protection for live-attenuated vaccines, since that may be the best indicator of B-cell 367 
priming. Recent efforts by PATH, the WHO, and the National Institute for Biological 368 
Standards and Control (NIBSC) examined the variability of RSV neutralization 369 
assays across laboratories and recommended steps for improved standardization 370 
globally(84), resulting in the development of a new WHO International Standard for 371 
Antiserum to RSV with 1000 International Units of RSV subtype A neutralizing 372 
activity per vial now available through the NIBSC(85). Standardization of other 373 
frequently used immunologic assays such as PCA, ELISA and T-cell assays has not 374 
yet taken place. 375 
 Once infection of the lower airways is established, CD8 T-cells play an 376 
important role in viral clearance(86). Th2-biased responses have been associated 377 
with animal models of RSV ERD and measurement of Th1 and Th2 responses are 378 
considered important to predict safety of vaccine candidates other than live-379 
attenuated vaccines in clinical trials in young children.  380 
 Animal models are important for preclinical development of vaccine 381 
candidates and assessing the possibility of enhanced disease. Alveolitis in the cotton 382 
rat and priming of a Th2 response in mice are considered markers to assess possible 383 
ERD; there is no consensus on the ability to reproduce ERD in calves(87).  384 
 Although we discuss several potential immunological correlates of protection 385 
for vaccine trials, we considered cell-mediated immunity beyond the scope of the 386 
manuscript. However, we highlight the different aspects of the expected immune 387 
response for all 19 vaccine candidates and mAbs in clinical development in Table 3. 388 
A definitive threshold for protection against RSV disease remains elusive. So far no 389 
vaccine candidates have been tested in the experimental human infection model, but 390 
the model provides a unique opportunity to test vaccine candidates in the natural 391 
host despite practical and ethical challenges(88).Ultimately, the outcome of large-392 
scale vaccine trials will inform which immunologic measures correspond to 393 
protection from clinical RSV disease. 394 
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 395 
Vaccine strategies 396 
We have divided vaccines in clinical development into four categories in accordance 397 
with the PATH RSV vaccine and mAb snapshot: particle-based, vector-based, subunit 398 
and live-attenuated/chimeric vaccines(21). We have also included mAbs in clinical 399 
development for the prevention of RSV ALRI. In the snapshot there are 43 vaccines 400 
and 4 mAbs in development of which 19 are in clinical stage development. An 401 
important consideration for all vaccines is not only to prevent severe RSV disease, 402 
but also to avoid the risk of priming for RSV ERD. Based on our current 403 
understanding of the underlying mechanisms leading to RSV ERD, caution should be 404 
taken in the use of protein-based vaccines in RSV naïve individuals. Replication 405 
deficient vectors, engineered to induce CD8 T cell responses expressing RSV 406 
antigens intracellularly, are considered more similar to live-attenuated virus 407 
vaccines which have been shown not to cause ERD in this population. In Table 1 we 408 
provide a comprehensive overview and more detailed comparison of all 409 
characteristics of the 19 vaccine candidates and mAbs in clinical development. 410 
 411 
Particle-based vaccines 412 
The RSV F nanoparticle-based vaccine platform is currently being evaluated for 413 
protection of three target populations: (1) infants through maternal vaccination, (2) 414 
children between 6 months and 5 years, and (3) older adults. These vaccine 415 
candidates utilize aggregates of a modified stabilized F protein which exhibits the 416 
post-F morphology(89). The maternal RSV F nanoparticle vaccine candidate is 417 
farthest along in clinical development and the PREPARE trial has entered the third 418 
year of a phase III trial to enroll up to 8,618 pregnant women at 80 sites in 11 419 
countries(43). In January 2018 an informational analysis of the phase III trial was 420 
announced in which the vaccine candidate successfully targeted an efficacy 421 
threshold against the primary endpoint in infants at day 90 of >40%(90). Second in 422 
clinical development is the RSV F nanoparticle vaccine for older adults. Despite lack 423 
of efficacy in a phase III trial (RESOLVE) with a non-adjuvanted vaccine candidate, 424 
development was continued in a phase II roll-over study initiated in January 2017 in 425 
Australia in 300 adults. The aim of this rollover trial is to determine whether 2 dose 426 
regimens with an adjuvant (Matrix-M, a saponin-based adjuvant, or aluminum-427 
phosphate) may increase the magnitude and quality of the immune response in this 428 
population. The results from the RESOLVE trial in older adults suggested vaccine 429 
efficacy in adults with COPD, leading to considerations to initiate a future trial in this 430 
older adult population at high risk for severe RSV infection(43). Finally, the phase I 431 
trial was completed in young children 24-72 months of age in 2016, but no data 432 
have been published yet(91). 433 
SynGEM is a particle-based needle-free vaccine candidate containing the RSV 434 
F protein attached to empty bacterial particles made from Lactococcus lactis. In this 435 
vaccine platform an antigen is presented by a bacterial particle. An influenza vaccine 436 
candidate in clinical trials which uses the same vaccine platform, has shown both 437 
local and systemic antibody responses(92) but needs further optimization for RSV 438 
vaccination. The preliminary results of immunogenicity testing have been reported. 439 
The immunogenicity of this vaccine was evaluated after delivery as a nasal spray to 440 
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healthy adult volunteers. Two intranasal doses of SynGEM were administered 28 441 
days apart at low or high dose in 24 subjects per group (6 subjects in each group 442 
receiving placebo, double blinded). Assays of serum RSV F-specific antibodies, PCA, 443 
and F-specific IgA indicated some immunogenicity, but the results did not reach the 444 
threshold set for continuation to viral challenge and the studies were suspended in 445 
2017 (Openshaw and Chiu, personal communication). 446 
 447 
Vector-based vaccines 448 
There are five vector-based vaccines in clinical development. The first uses a 449 
modified vaccinia virus Ankara (MVA), a replication-defective smallpox viral vector, 450 
and the remaining four vaccine candidates employ an adenovirus vector to display 451 
viral antigens. The MVA vector has been safely used in vaccines for other infectious 452 
diseases(93). This vaccine candidate, MVA-BN-RSV, induces both humoral and cell-453 
mediated responses by displaying four vaccine antigens: F, G, N and M2-1. Phase II 454 
results in healthy older adults from this candidate will soon be announced.  455 
 The second vector-based vaccine candidate, VXA-RSV-f, uses an innovative 456 
platform with an adenovirus 5 based oral tablet that is stable at room temperature. 457 
Using the same oral adenovirus vaccine delivery platform, a phase I trial for 458 
influenza has been conducted, which showed neutralizing antibody responses 459 
against influenza and no interference of pre-existing vector immunity(94). 460 
Preclinical studies for the RSV vaccine candidate in the cotton rat model showed an 461 
increase in anti-F antibodies and protection against RSV challenge(95). In the older 462 
adult population immunosenescence may be characterized by impaired T-cell 463 
responses to RSV(96,97). This vaccine candidate which induces a humoral response 464 
may be a promising intervention in this population.. 465 
 Third and fourth, Ad26.RSV.preF, is a vaccine candidate being developed for 466 
two populations: the older adult and the pediatric population. In this candidate pre-467 
F antigen is expressed in the human adenovirus strain 26, a vector with a favorable 468 
safety profile when used for other infectious diseases(98,99). Previously, the 469 
vaccine candidate vector expressed post-F as antigen (FA2) but has now been 470 
changed to stabilized pre-F conformation. The stabilized pre-F protein has 5 amino 471 
acid changes from wild-type, and is stable at 4C and heat-stable(50). With the 472 
expectation that this vaccine candidate will induce highly neutralizing antibodies 473 
against pre-F, phase II trials will be conducted in RSV-seropositive children. In 474 
December 2017 a phase II trial was initiated comparing concomitant administration 475 
of RSV vaccine and seasonal influenza vaccine versus seasonal influenza vaccine 476 
alone in healthy older adults(100). 477 
 Fifth, ChAd155-RSV, a replication-incompetent chimpanzee adenovirus 155 478 
has been used as a vector for the F, N and M2.1 proteins. The anticipated use for this 479 
pediatric vaccine is to start immunization at two months of age, and to use two 480 
doses alongside the normal pediatric vaccination schedule, instead of 481 
seasonally(101). This vaccine candidate is currently being evaluated in 12-23 month 482 
old RSV seropositive children. In the future, there are plans to conduct clinical trials 483 
in seronegative children sequentially from older to younger ages (12-24 months 484 
followed by 6-12 months and subsequently 2-6 months of age) to ensure safety in 485 
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RSV-naïve populations. Results of phase II trials are expected to be announced in 486 
2020.  487 
In summary, vector-based vaccines are used to display various RSV viral 488 
proteins and three of these vaccine candidates are in phase II trials. 489 
 490 
Subunit vaccines 491 
Due to concerns of ERD associated with protein-based vaccines, subunit vaccines 492 
are only in development for pregnant women and older adult populations. One 493 
subunit vaccine in development is the GSK RSV F vaccine candidate, which uses a 494 
version of soluble secreted F protein empirically engineered to maintain the Pre-F 495 
conformation. Phase I results demonstrated safety and immunogenicity as 496 
evidenced by RSV neutralizing antibody response in healthy men(102). However, a 497 
phase II trial scheduled for 2017 was halted due to instability of the pre-F antigen 498 
during manufacturing. 499 
 Structure-guided stabilization of the pre-F conformation has yielded a 500 
subunit vaccine candidate, DS-Cav1. The stabilization includes a foldon 501 
trimerization domain, the introduction of cysteine residues to form a disulfide bond, 502 
and cavity-filling hydrophobic residues(52). The vaccine is able to preserve 503 
neutralization-sensitive epitopes on a functional pre-F form of the viral surface 504 
protein. In preclinical studies the subunit vaccine induced high levels of RSV-505 
neutralizing antibodies in mice and non-human primates(52). Preliminary results 506 
from the phase I trial, VRC 317, are promising and are expected to be published 507 
soon. 508 
 DPX-RSV is a vaccine candidate with a unique choice of vaccine antigen; the 509 
extracellular domain of the SH protein of RSV(60). The DepoVax technology allows 510 
for a prolonged exposure of antigen and adjuvant, and aims to induce ADCC using a 511 
liposome and oil-based depot(103). The antigen and adjuvant are encapsulated in a 512 
liposome, lyophilized and suspended in oil and the process is expected to produce 513 
vaccines with long shelf-life stability(104). Phase I results on safety and 514 
immunogenicity in the older adult population have been released and are expected 515 
to be published from this investigator-initiated study. 516 
 517 
Live-attenuated and chimeric vaccines 518 
In the context of historical concerns for enhanced RSV disease, live-attenuated 519 
vaccines can be considered safe for RSV naïve infants, based on consistent clinical 520 
study results showing that these candidates do not prime for ERD following 521 
subsequent exposure to wild-type RSV after vaccination(105). Another benefit of 522 
live-attenuated vaccines against RSV in young infants is their ability to replicate in 523 
the respiratory tract despite the presence of maternally-acquired antibodies, and to 524 
elicit a broad humoral and cellular response(106). Live-attenuated vaccines are 525 
likely limited to the pediatric population under two years of age, as pre-existing 526 
immunity in older populations might not permit sufficient replication to generate 527 
protective immune responses. Safety could be a concern for intranasal live-528 
attenuated vaccines, in particular if attenuation is insufficient. However, evaluation 529 
of current vaccines has not shown evidence of increased rates of vaccine-associated 530 
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ALRI or fever, though there may be increased rates of rhinorrhea, similar to what 531 
has been observed with the live-attenuated influenza vaccines. 532 
 Five live-attenuated vaccine candidates in phase I clinical trials are being 533 
developed in partnership with the National Institutes of Health. Live-attenuated 534 
vaccines face the challenge of achieving sufficient attenuation to be safe while 535 
remaining immunogenic enough to induce a protective immune response. An 536 
improved understanding of the RSV viral genome has informed the development of 537 
new vaccine candidates that may overcome this challenge. Two main modifications 538 
to the RSV genome have been engineered through reverse genetics: the ΔM2-2 539 
deletion which attenuates viral replication and upregulates antigen expression(37) 540 
as well as the ΔNS2 deletion which reduces viral suppression of host interferon 541 
thereby boosting the innate immune response. RSV MEDI ΔM2-2 reduced viral 542 
replication while inducing a strong primary serum neutralizing antibody as well as 543 
potent anamnestic response in RSV-seronegative infants and children(37). Further 544 
results from phase I clinical trials with the other live-attenuated vaccine candidates 545 
are expected. 546 
The only chimeric vaccine candidate, rBCG-N-hRSV, currently in clinical 547 
development is delivered via a BCG strain. BCG has a safe profile in newborns and 548 
infants, induces a Th1 response(107,108), and allows for combined vaccination 549 
against two major respiratory pathogens: Mycobacterium tuberculosis and RSV. Not 550 
only is the Th1 cellular response important in protecting against lung pathology, 551 
inflammation and viral replication(109) but the candidate also induces a humoral 552 
response. The antigen presented by this vaccine candidate is the RSV N protein(110). 553 
Presently, this candidate is the only vaccine candidate intended for administration 554 
to newborn infants(110). 555 
 556 
Monoclonal antibodies 557 
A promising highly potent monoclonal antibody has emerged as a passive 558 
administration strategy to prevent severe RSV infection. MEDI8897, also known as 559 
nirsevimab, was optimized from the human antibody D25 that targets antigenic site 560 
Ø on the pre-F conformation, which is more neutralization sensitive than the 561 
palivizumab epitope, antigenic site II. Using the YTE technology which extends 562 
antibody half-life as well as modulates ADCC(111), the three-fold increase in half-563 
life of MEDI8897(112) compared to palivizumab offers the possibility of passive 564 
protection for all infants for an entire season through a single intramuscular 565 
injection. The intended use is for both term and preterm infants entering their first 566 
RSV season. Passive vaccination with an extended half-life antibody offers an 567 
approach to protecting infants that is safe and may be reasonably priced. 568 
Representatives of the pharmaceutical company have indicated that they expect 569 
vaccine-like pricing for MEDI8897. Given the increased potency, the extended half-570 
life, and the required dose, it is expected that the cost to protect an infant during the 571 
RSV season can be kept relatively low(66). 572 
 573 
Other approaches not in clinical development 574 
Other emerging approaches not yet in clinical development include nucleic acid-575 
based vaccines(113). Importantly these vaccines induce a T-cell response mimicking 576 
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the response to live virus infection. Both DNA and messenger RNA (mRNA) vaccines 577 
against RSV have shown promising results in preclinical studies(113). Notably, 578 
through a collaboration with the Bill & Melinda Gates Foundation, an mRNA 579 
technology vaccine platform for HIV and rotavirus has also expanded to include RSV. 580 
Another vaccine approach in preclinical development is a whole-inactivated vaccine 581 
to be delivered intranasally via a nanoemulsion technology, for which development 582 
has been supported by the Bill & Melinda Gates Foundation(114). Furthermore, 583 
with the first of the palivizumab patents expiring in October 2015 and the last in 584 
2022, there has been active development to produce a biosimilar in order to provide 585 
a low-cost RSV preventive intervention.. 586 
 587 
Considerations by regulatory agencies and the World Health Organization 588 
The FDA has articulated that differences between high income countries (HICs) and 589 
LMICs are not particularly relevant to regulatory decisions, though a bridging study 590 
in the US must be performed if all clinical trials have been performed outside of the 591 
US(115). The EMA does not require that trials intended to support a regulatory 592 
decision are conducted in the European Union. Other considerations in population 593 
selection for vaccine trials mentioned by EMA include: first testing a vaccine 594 
candidate in a seropositive before testing in a seronegative population, testing a 595 
maternal vaccine in non-pregnant women of child-bearing age before testing in 596 
pregnant women, and including older adults with comorbidities in vaccine trials. No 597 
particular considerations were mentioned for population selection in studies for 598 
mAbs. In October 2017 the EMA released draft guidelines for the clinical evaluation 599 
of RSV prophylactic interventions which included guidance regarding trial design, 600 
assessment of efficacy, and safety(116). The draft guidelines will be revised after a 601 
period of public consultation based on comments and new publications. 602 
 The WHO has recognized the importance of RSV as a global health problem 603 
and has identified the development of RSV vaccines as a priority for the WHO 604 
Initiative for Vaccine Research and for Biological Standardization. WHO recently 605 
developed RSV vaccines preferred product characteristics and research and 606 
development technical roadmap documents(117,118). Further guidance for 607 
development will contribute to adequate policy-making. WHO standardization 608 
activities led to the development and establishment of the first international 609 
standard for antiserum to RSV. Development of guidelines for evaluation of quality, 610 
safety and efficacy of RSV vaccines has been initiated and will be part of consultation 611 
with regulators, manufacturers and academia in 2018 with the aim of finalizing it in 612 
2019. Further discussion on guiding principles for mAbs is needed before 613 
proceeding with the development of the WHO Guidelines. These and other WHO 614 
standards serve as a basis for setting national regulatory requirements as well as 615 
WHO prequalification.  616 
Finally, the WHO is now performing a surveillance pilot study in 14 countries 617 
to test the feasibility of using the Global Influenza Surveillance and Response System 618 
platform for RSV surveillance and it is expected that this pilot will contribute to our 619 




Discussion   623 
Challenges in RSV vaccine design include concerns of ERD post-vaccination, lack of 624 
definitive immunologic correlates of protection, lack of consensus regarding clinical 625 
endpoints, and limited natural immunity following RSV infection. Despite these 626 
challenges, recent developments such as an understanding of the structural biology 627 
of the RSV fusion protein as well as lessons learned from late-phase vaccine trial 628 
failures have informed the field as it moves forward.  629 
We attempted to collect data regarding expected plans for access to a 630 
preventive intervention in LMICs and expected pricing for all vaccine candidates, 631 
however this information is not publicly available. The only information obtained 632 
regarding expected pricing was for MEDI8897, though a more specific estimate than 633 
vaccine-like pricing was not available. Given that the most severe RSV infection 634 
occurs in LMICs(17), information regarding LMIC target countries and potential 635 
pricing for vaccine candidates will be essential to facilitate access to vaccines 636 
worldwide, especially in areas where the mortality burden is highest. In LMICs the 637 
most important target for vaccine candidates is young children(120). A mechanism 638 
should be introduced to ensure that information regarding expected pricing and 639 
access to interventions is transparent and available in the public domain. RSV 640 
vaccines and mAbs will be considered in the development of the Vaccine Investment 641 
Strategy by GAVI, the Vaccine Alliance in 2018(121).  642 
A vaccine trial may be considered a probe study to determine whether a 643 
causal relationship exists between RSV infection and asthma, a longstanding 644 
question in the field. If long-term follow-up had been undertaken during the pivotal 645 
RSV prevention trials using palivizumab, these trials would now have provided 20 646 
years of follow-up on respiratory morbidity after RSV prevention in high-risk 647 
infants. Lack of long-term surveillance for airway morbidity in vaccine trials are 648 
missed opportunities to provide novel scientific insights important not only to 649 
understand the pathogenesis but also the long-term vaccine efficacy against airway 650 
morbidity following RSV infection. In addition to wheeze, objective outcomes, such 651 
as lung function measurements including demonstration of bronchial 652 
hyperreactivity and IgE measurements will ideally be incorporated in vaccine trials 653 
to fully understand the impact of RSV prevention on asthma development.  654 
 Viral interference, in which RSV inhibits infection by other viruses, is 655 
becoming an increasingly important concept to understand in the context of an 656 
approved RSV vaccine. RSV vaccination may conceivably result in an increased 657 
prevalence of other respiratory viruses. There is evidence supporting viral 658 
interference for influenza vaccination(122,123), for RSV prevention(124,125), and 659 
during the RSV season in the absence of RSV(126). It is important for vaccine trials 660 
to examine this phenomenon by evaluating the incidence of all-cause ALRI, as well 661 
as RSV-specific ALRI, to better understand the implications of viral interference for 662 
an RSV vaccine. 663 
 This review provides an extensive overview of the 19 vaccine candidates and 664 
mAbs in clinical trials to prevent RSV infection.  RSV vaccine development is moving 665 
rapidly and shows promise to address an unmet global health problem. Vaccines for 666 
various target populations are in clinical development. One vaccine candidate and 667 
one mAb are in late phase trials (IIb/III) and aim to prevent the disease burden in 668 
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young infants. Despite some recent failures, RSV vaccine candidates and mAbs in 669 
clinical development hold the promise that a preventive intervention for RSV is on 670 
the horizon. 671 
 672 
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MONOCLONAL ANTIBODY (mAb) 




mutation in Fc 
N/A N/A Antibody 
targeting site 
Ø of the F 
protein of 
RSV with an 
extended 
half-life 
























N/A PhI; well-tolerated,, 
Mean half-life 85-117d; 
time to max concentration  
5-9 days; bioavailability 77% 
in healthy adults (n=136) 
(146) 
      
 
        
 
Legend: N/A: not applicable or not available, IM: intramuscular, ID: intradermal, IN: intranasal, IV: intravenous; ARD: acute 
respiratory disease, PCA: palivizumab-competing antibodies, P: pediatric, M: maternal, O: older adults, SHe: small hydrophobic 
protein ectodomain; RSV ARD: all symptomatic respiratory disease due to RSV; msLRTD: moderate-severe RSV-associated 
lower respiratory tract disease; NIAID: National Institutes of Allergy and Infectious Diseases; VRC: Vaccine Research Center; 




Table 2 Overview of vaccines and mAbs by target population 
 
Target Population Vaccine Vaccine type 
Pregnant mothers   
Third trimester RSV F nanoparticle 
(Novavax) 
Nanoparticle 
Third trimester RSV F 
(GSK) 
Subunit 
 RSV F protein (NIH/NIAID/VRC) Subunit 
Pediatric   
6m-5y RSV F nanoparticle 
(Novavax) 
Nanoparticle 
Start 2m Adenovirus 
(GSK) 
Vector 




(Pontificia Unversidad Catolica de 
Chile) 
Chimeric 
 RSV D46 cp ΔM2-2  
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV LID ΔM2-2 1030s  
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV ΔNS2 Δ1313 I1314L 
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV D46/NS2/ N/ΔM2-2-HindIII 
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 






Older adults   
 RSV F nanoparticle 
(Novavax) 
Nanoparticle 
 RSV BLP 
(Mucosis) 
Nanoparticle 
 MVA (Bavarian Nordic) Vector 
 Adenovirus (Vaxart) Vector 
 Adenovirus (Janssen) Vector 
 DPX-RSV-SH Protein 
(Immunovaccine) 
Subunit 
 RSV F protein 
(NIH/NIAID/VRC) 
Subunit 
Legend: m: months; y: years
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Table 3: Expected immune response and previous successes for vaccine candidates and monoclonal antibodies 
 
Vaccine Target Population Pre-F Immunity* (86) Immune response Mucosal/Systemic 
Nanoparticle     
RSV F Nanoparticle 
(Novavax) 
M Pre-F < post-F Broadly neutralizing 
antibodies 
systemic 
RSV F Nanoparticle 
(Novavax) 
O Pre-F < post-F Broadly neutralizing 
antibodies 
systemic 
RSV F Nanoparticle 
(Novavax) 





O & P unclear F confirmation Activation of B & T cells; 
local secretion of 
neutralizing IgA in the 
nose; production of IgG 
neutralizing IgG in the 
blood 
mucosal & systemic 
Vector     
MVA 
(Bavarian Nordic) 
O Pre-F < post-F B & T cell response; 





O Pre-F > post-F B & T cell response; 
neutralizing antibodies 
against F antigen; CD8 T 
cells against F, N and 
M2.1 antigens 
systemic 
Adenovirus (Vaxart) O Pre-F < post-F B & T cell immunity, 
protection at mucosal 
surface 
mucosal > systemic 
Adenovirus (Janssen) P Pre-F B & T cells systemic 
Adenovirus (Janssen) O  Pre-F B & T cells systemic 
Subunit     
RSV F (GSK) M Pre-F B & T cell response systemic 
DPX-RSV (Dalhousie 
University) 
O none  systemic 
RSV F protein 
(NIH/NIAID/VRC) 
O & M Pre-F  systemic 
Live-attenuated     
BCG/RSV 
(Pontificia Universidad 
Catolica de Chile) 
P Pre-F & post-F B & T cell response; Th1 
polarized response; 
antibodies against N, F, G 
systemic 
RSV D46 cp ΔM2-2 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response; 
enhanced antibody 
production due to 
increased antigen 
production from M2-2 
deletion 
mucosal & systemic 
RSV LID ΔM2-2 1030s 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response; 
enhanced antibody 
production due to 
increased antigen 
production from M2-2 
deletion 
mucosal & systemic 
RSV ΔNS2 Δ1313/I1314L 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response mucosal & systemic 
RSV D46 ΔNS2 N ΔM2-2 
HindIII 
P Pre-F & post-F B & T cell response; 
enhanced antibody 




production due to 
increased antigen 
production from M2-2 
deletion 
RSV LID cp ΔM2-2 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response; 
enhanced antibody 
production due to 
increased antigen 
production from M2-2 
deletion 
mucosal & systemic 
Monoclonal Antibody   
MEDI8897 
(MedImmune) 
P N/A N/A N/A 
 
Legend: Pre-F: prefusion conformation of the RSV F protein; Post-F: postfusion conformation of the RSV F protein; N: RSV 
nucleocapsid protein; F: RSV fusion protein; G: RSV attachment protein; O: older adults; M: maternal; P: pediatric. 
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Figure 1: RSV global burden of disease in children under 5 years of age: key facts and figures   
 
 
Figure 1 Incidence is shown worldwide for children under 5 years of age unless otherwise stated. The hospital admission rate 
of 15.9 hospital admissions per 1000 neonates per year is in developing countries. The RSV ALRI hospitalization 63.9 among 
premature infants <1 year is reported per 1000 children per year globally. Legend: OR: odds ratio; LRTI: lower respiratory 
tract infection, RSV: respiratory syncytial virus, HIC: high income country, *: compared to children who survived RSV 
hospitalization and were mechanically ventilated. References: (a)(1) (b)(78) (c)(147) (d)(148) (e)(149) (f)(150)  
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Figure 2: Overview of Vaccine candidates and monoclonal antibodies in clinical trials per preventive approach including 
candidates for which development was recently halted 
 
Legend: For vaccine candidate names listed in gray development has been halted since the last RSV therapeutics review 
performed in 2015(20). Abbreviations: PH I: phase I; PH II: phase II; PH III: phase III.  
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Abstract (word count: 132167/150200) 
 
The global burden of disease caused by respiratory syncytial virus (RSV) is 
increasingly recognized, not only in infants, but also in older adults. Advances in 
knowledge of the structural biology of the RSV surface fusion (F) glycoprotein have 
revolutionized RSV vaccine development by providing a new target for preventive 
interventions. The RSV vaccine landscape has rapidly expanded to include 19 
vaccine candidates and  and monoclonal antibodies (mAbs) in clinical trials, 
reflecting the urgency of reducing this global health problem and hence the 
prioritization of RSV vaccine development. The candidates include mAbs and 
vaccines using four approaches: (1) particle-based, (2) live-attenuated/chimeric, (3) 
subunit, (4) vector-based. Late phase RSV vaccine trial failures highlight gaps in 
knowledge regarding immunologic protection and provide lessons for future 
development. In this review we highlight promising new approaches to RSV vaccine 
design and provide a comprehensive overview of RSV vaccine candidates and mAbs 
currently in clinical development to prevent one of the most common and severe 
infectious diseases in young children and older adults worldwide.
 7 
Search strategy and selection criteria 1 
References for this review were identified through a search of PubMed for clinical 2 
trials with “syncytial” in the title published after January 1, 2013 with no language 3 
restrictions, through April 3, 2018. We did not intend to do a systematic review of 4 
the literature. No inclusion or exclusion criteria were used. Instead, we selected 5 
articles that were most relevant to the subheadings used in this review. The PATH 6 
RSV vaccine and mAb Snapshot was used as a reference to identify all vaccine and 7 
mAb candidates in clinical trials. ClinicalTrials.gov as well as the WHO vaccine 8 
pipeline tracker for RSV were used to identify all relevant trials for these vaccine 9 
candidates and mAbs. Additional data was collected during the RSV Vaccines for the 10 
World Conference on November 29- December 1, 2017 and through pharmaceutical 11 
websites for the respective vaccine and mAb candidates.  12 
 8 
Introduction 13 
Respiratory syncytial virus (RSV) acute lower respiratory infection (ALRI) has 14 
gained recognition as a global health problem with a high burden of disease and no 15 
vaccine licensed for prevention. In children under 5 years, it is estimated that 33.1 16 
million episodes of ALRI, 3.2 million hospital admissions and as many as 118,200 17 
deaths were attributable to RSV worldwide in 2015(1) [Figure 1]. Although often 18 
characterized as a pediatric disease, the burden of RSV in adults is alsorepresents a 19 
significant health burden. with Mortality attributable to RSV in adults ≥65 years of 20 
age is estimated to be 7.2 per 100,000 person years(2) and a mortality rate of 7 to 21 
8% of RSV ARLI among older hospitalized adults hospitalized with RSV ALRIwas 22 
reported to result in death  in the United States(3) in the United States(US). The 23 
mortality attributable to RSV in adults ≥65 years of age is estimated to be 7.2 per 24 
100,000 person years (3). RSV vaccine candidates aim to protect at least three 25 
target populations that are at risk for severe RSV disease: (1) young infants through 26 
passive immunization, (2) older infants and young children through active 27 
immunization, and (3) older adults.  28 
Development of effective RSV vaccines and monoclonal antibodies (mAbs) 29 
presents both opportunities and challenges. First, concerns of enhanced respiratory 30 
disease (ERD) following vaccination with the formalin-inactivated RSV (FI-RSV) 31 
vaccines in the 1960s have complicated the design and testing of RSV vaccines(4). 32 
ERD occurred in RSV-naïve infants who experienced infection with community-33 
acquired wild-type RSV following receipt of FI-RSV. Decades of research have 34 
revealed that in these FI-RSV primed infants, natural RSV infection triggered a 35 
strong but non-neutralizing antibody response(5), followed by a T helper 2 (Th2) 36 
skewed immunologic response(6). The failure to mount a protective cytotoxic T 37 
lymphocyte (CTL) response was coupled with excess lung eosinophilia and 38 
neutrophilia, monocytic infiltration, and immune complex deposition in the lungs(7). 39 
Current vaccine candidates, especially those designed for RSV naïve infants and 40 
children, must demonstrate safety by avoiding these immunologic hallmarks of ERD. 41 
Second, an absolute correlate of protection against a clinically relevant RSV infection 42 
remains elusive, although cell-mediated immunity(5), mucosal IgA(6) and potent 43 
neutralizing antibodies(7) have been associated with decreased disease severity.  44 
Recently, three phase IIb/III trials (two vaccine trials in older adults(8,9) and 45 
one mAb trial in infants(10)) failed to meet clinical endpoints. The In addition to 46 
possible inadequacies in trial design and implementation, the failure of these 47 
vaccine and mAb candidates demonstrates the continued gaps in knowledge 48 
regarding immunologic mechanisms of protection in the different target populations.  49 
Another challenge to RSV vaccine design is the lack of consensus regarding clinical 50 
endpoints of vaccine trials though attempts have been made to define these for RSV 51 
both prevention trials(11–13) and treatment trials(17). Furthermore, these 52 
endpoints may differ based onaccording to the target population. Finally, a 53 
consideration in RSV vaccine development is the limited protection conferred by 54 
immune responses elicited by natural RSV infection. Natural immunity provides 55 
only transient protection against subsequent infection and re-infection occurs 56 
frequently(14) though the most severe RSV disease is usually observed during the 57 
primary infection. Disease in older children and healthy younger adults is typically 58 
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mild. Monoclonal antibodies circumvent the problem of transient immunity to RSV 59 
and an immature immune response to vaccination in young infants at risk of severe 60 
disease. An ideal RSV vaccine candidate should prevent severe disease in at risk 61 
populations. Certain vaccines might also lessen person-to-person transmission and 62 
thereby provide secondary benefits in those who cannot benefit directly from 63 
vaccination(15).  64 
 Despite these obstacles, there are several opportunities for RSV vaccine and 65 
mAb  development. First, the RSV disease burden has received increasing attention 66 
from international stakeholders such as the World Health Organization (WHO)(16) 67 
and the Bill & Melinda Gates Foundation based on better estimates of RSV-68 
associated mortality worldwide(17). Second, the discovery and of the structure and 69 
stabilization of the prefusion (pre-F) conformation of the RSV F protein has 70 
advanced the fieldprovided a new target for vaccines and mAbs(18,19) as p by 71 
showing that pre-F specific antibodies may be more potent in protecting against 72 
RSV LRTI than antibodies that also bind the postfusion (post-F) conformation 73 
antibodies in protecting against RSV ALRI.  and by thus providing a new target for 74 
vaccines and mAbs(21,22). Third, pharmaceutical companies have recognized the 75 
urgent unmet need of RSV prevention and prioritized the development of RSV 76 
vaccines and mAbs.  77 
In 2015, a review of new RSV prevention and therapeutic strategies was 78 
conducted which demonstrated that 10 vaccines were in clinical development(20). 79 
An update of that review is necessary in light of the recent failures and new vaccine 80 
candidates in the last several few years.  In this review, we show that only 50% 81 
(5/10) of candidates from 2015 are currently continuing in clinical trials and 14 82 
additional new vaccine candidates have entered clinical trials [Figure 2]. In the 83 
context of RSV as an increasingly recognized global health problem, these rapid 84 
changes and expansion show the prioritization of RSV vaccine and mAb 85 
development.  86 
  87 
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Methods 88 
A data collection template was designed for all vaccines in clinical development 89 
according to the PATH RSV vVaccine and mAb snapshot Snapshot (updated 90 
November 2017 (21)) [Supplementary Table 1]. Gaps in knowledge were identified 91 
by searching PubMed, clinical trial registries, WHO, European Medicines Agency 92 
(EMA) and pharmaceutical websites for each vaccine candidate, with no date or 93 
language restrictions, on January 31, 2018through April 3, 2018 (NM, ACL, NH, IR, 94 
EP, JS). We did not intend to do a systematic review of the literature. No inclusion or 95 
exclusion criteria were used. Instead, we selected articles were selected that were 96 
most relevantbased on relevance to the subheadings used in this review as well as 97 
each vaccine candidate or mAb in clinical development. To supplement the data 98 
collected and the identified gaps in knowledge,Furthermore, data for this review 99 
were systematically collected using athe data collection template [Supplemental 100 
Table 1] at the RSV Vaccines for the World conference organized by the Respiratory 101 
Syncytial Virus Network (ReSViNET) from November 29 - December 1, 2017 in 102 
Malaga, Spain. The goal of this meeting was to share scientific data and expertise on 103 
RSV vaccine development, and to connect stakeholders involved in RSV research. 104 
During the meeting information was collected (NM, ACL, NH, IR, EP, JS) from 105 
scientific presentations, posters and personal communications. 106 
 We included all vaccine candidates and mAbs in clinical development 107 
according to the PATH RSV Vaccine vaccine snapshot and mAb snapshotSnapshot. 108 
Vaccines were divided into four major groups: particle-based, vector-based, live-109 
attenuated/chimeric and subunit vaccines. Immunoprophylaxis with mAbs was 110 
included as a fifth category. 111 
 112 
RSV Vaccine History 113 
RSV vaccine development started shortly after the first identification of the virus in 114 
humans in 1957(22). However, ERD upon natural RSV infection after vaccination 115 
with a formalin-inactivated RSV (FI-RSV) candidate in a series of trials in the 1960s 116 
severely hindered inactivated virus and subunit vaccine development for many 117 
years. In the youngest age cohort of RSV naïve infants,group, 20 of 31 of RSV naïve 118 
infants were infected with community-acquired wild-type RSV during the next RSV 119 
season and 16 (80%) required hospitalization including two deaths(4) in whom 120 
ERD was documented. ERD occurred in RSV-naïve infants who experienced 121 
infection with community-acquired wild-type RSV following receipt of FI-RSV. 122 
Decades of research have revealed that in thesepriming with FI-RSV vaccine primed 123 
infants, natural RSV infection triggered a strong but non-neutralizing antibody 124 
response(23),  followed by a T- helper 2 (Th2) skewed immunologic response(24) 125 
which led to ERD upon natural RSV infection. Other aspects of the immune response 126 
implicated in ERD include distinct subsets of CD4 T-cells(25) and memory CD8 T-127 
cells(26). The failure to mount a protective cytotoxic T- lymphocyte (CTL) response 128 
was coupled with excess lung eosinophilia and neutrophilia, monocytic infiltration, 129 
and immune complex deposition in the lungs(27).  130 
Nevertheless, work continued on development and human testing of live-131 
attenuated RSV vaccine candidates. In the following 60 years, only two products 132 
were licensed for prevention of RSV.: The first product was RSV intravenous 133 
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immunoglobulin (RSV-IVIG), a polyclonal immunoglobulin preparation with high 134 
titers of anti-RSV neutralizing activity , that was approved in the United StatesUS 135 
and Canada and discontinued after 2003. when RSV-IVIG was replaced by the 136 
second approved product palivizumab, a humanized mAb directed against the RSV F 137 
glycoprotein(28,29). Since its initial approval in 1998, palivizumab remains the only 138 
licensed preventive intervention against RSV after demonstrating a reduction of 139 
39% to almost 80% reduction of RSV hospitalizations in preterm infants < 35 weeks 140 
gestational age with and without chronic lung disease respectively(29). Palivizumab 141 
has an excellent safety profile and is indicated for the prevention of severe RSV ALRI 142 
in children born prematurely, with congenital heart disease, for with chronic lung 143 
disease(30).  144 
MotivazumabMotavizumab, a higher affinity variant of palivizumab, was 145 
developed was developed in early 2000 but was withdrawn discontinued in 146 
2010(31). In a non-inferiority head-to-head comparative trial designed to show 147 
non-inferiority to palivizumab, motavizumab recipients had a slightly higher 148 
frequency of mild skin reactions following administration when compared to 149 
palivizumab(32). However, in a placebo-controlled trial, motavizumab was highly 150 
efficacious against inpatient and outpatient RSV LRI in healthy term American 151 
Indian infants (33). Without Nevertheless, without evidence of superiority 152 
compared to palivizumab, for protection from RSV-related hospitalization, evidence 153 
of slightly higher side effects, and no plan for dose reduction or cost-saving, the 154 
product did not attain regulatory approval(34,35). However, in a placebo-controlled 155 
trial, motavizumab was highly efficacious against inpatient and outpatient RSV LRI 156 
in healthy term American Indian infants (35).  157 
With respect to vaccines for active immunization, many approaches targeted 158 
for RSV naïve children were evaluated pre-clinically over the years. Only Llive-159 
attenuated vaccine candidates were considered safe for clinical evaluation in these 160 
children because these vaccines are not expected to cause ERD(36). Over the past 40 161 
years, several biologically derived live-attenuated vaccine candidates with 162 
attenuating temperature sensitivity or cold-passage mutations were evaluated 163 
clinically, including in the pediatric population, but the appropriate balance of 164 
attenuation and immunogenicity, suitable for RSV-naive children and infants, 165 
remained elusive. After reverse genetics techniques became available in the 1990s, 166 
it became possible to design vaccines candidates with the appropriate level of 167 
attenuation, but with increased immunogenicity(37). While pediatric live-168 
attenuated RSV vaccine candidates were under continued evaluation since the 169 
1970s there were relatively few trials of RSV subunit vaccines conducted before 170 
2000, with the exception of the purified F protein (PFP) vaccines(38,39), and an RSV 171 
fusion (F) attachment (G), and matrix (M) subunit vaccine(40).  172 
Over the past 10 years development of preventive interventions for RSV has 173 
rapidly expanded. Currently, 19 vaccine candidates and mAbs for different target 174 
populations are in clinical trials, and many more are in preclinical development(21).  175 
 176 
Lessons from the vaccine and mAb graveyard 177 
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While vaccine development has accelerated, there have been three recent late-phase 178 
vaccine and mAb trial failures. It is important to distil lessons learned from these 179 
results to inform future vaccine development.  180 
1. A phase III double-blind, placebo-controlled trial (NURSERY) evaluating 181 
REGN2222 (suptavumab), a mAb against antigenic site V on the RSV pre-F 182 
protein, a major target for high-potency mAbs(41) was conducted at 250 sites 183 
in 19 countries. REGN2222 was administered once or twice during the 184 
respiratory season in to 1,149 healthy preterm infants < 6 months of age with 185 
a gestational age ≤35 weeks who were not eligible to receive palivizumab 186 
prophylaxis. and The trial did not meet its primary efficacy endpoint to 187 
prevent medically-attended RSV infections through day 150 of life(42). 188 
REGN2222 was accelerated from phase I to phase III due to promising results 189 
and the United StatesUS Food and Drug Administration (FDA) granted Fast 190 
Track designation in October 2015. A speculation for this failure may be 191 
inadequate dosing schedule in regard to the antibody half-life. The Ultimately, 192 
the basis for failing to meet the primary clinical endpoint is not known, as 193 
analyses of this late-stage failure have not yet been made public. 194 
2. The second candidate that failed to meet the predefined study endpoint in 195 
phase III clinical trials was the RSV F nanoparticle vaccine candidate for older 196 
adults, a candidate based on aggregates of full-length post-F. The results of the 197 
preceding phase II RSV F nanoparticle trial suggested the candidate vaccine 198 
might haveshowed modest efficacy(43) and.  promising immunogenicity 199 
measures, as determined by rise in geometric mean titer for IgG antibodies 200 
against the F protein and palivizumab competing antibodies (PCA), in the 201 
phase II trial(44). In the phase III trial, 11,58506 subjects ≥60 years of age 202 
were enrolled in 60 US sites in a double-blind placebo-controlled trial 203 
(RESOLVE) over a single season starting November 2015 with 330 182 days 204 
follow-up for the efficacy outcome. The trial was granted fast track designation 205 
by the FDA in 2016. (45). Although the vaccine showed promising results in 206 
phase II and comparable immunogenicity measures in the two phases as 207 
determined by neutralizing and palivizumab-competing antibody induction, 208 
However, the vaccine candidate failed to show efficacy against RSV moderate–209 
severe lower respiratory tract disease (ms-LRTD) in phase III results(9). 210 
Compared to the previous season, RSV acute respiratory disease (RSV-ARD) 211 
and ms-LRTD attack rates were lower than expected in the 2015 – 2016 212 
season (RSV-ARD: 2.0% versus 4.9% and RSV-msLRTD 0.4% versus 1.8% 213 
during the vaccine and previous season respectively). The pharmaceutical 214 
companyvaccine manufacturer speculates that the difference in vaccine 215 
efficacy observed may in part be due to thise lower attack rate as well as high 216 
pre-existing immunity in the study population(43). Another proposed 217 
explanation for failure of this vaccine candidate is that the quantity of the 218 
immune response to vaccination may not represent effective immunity. For 219 
example, PCA titers may not correspond to effective immunity as non-220 
neutralizing antibodies can also bind the palivizumab binding site and can 221 
interfere with the binding of neutralizing antibodies(46). In a post-hoc 222 
subgroup analysis, the vaccine candidate showed efficacy against 223 
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hospitalizations for all-cause chronic obstructive pulmonary disease (COPD) 224 
exacerbations from all causes(43). Upon further analysis of the phase III 225 
results, there was a non-statistically significant trend towards higher RSV 226 
microneutralization titers in adults without RSV-ARD when compared to 227 
adults with RSV-ARD, but this difference was not statistically significant. One 228 
conclusion that can be drawn from this trial is that late-phase clinical research 229 
for an RSV vaccine candidates should include evaluation across more than one 230 
RSV season.  231 
3. Development of the MEDI-7510 vaccine candidate, a subunit vaccine candidate 232 
for older adults, was discontinued after a phase IIb trial in North America, 233 
Europe, South Africa, and Chile. The vaccine candidate was evaluated in 1900 234 
adults ≥60 years after and the study failed to meet its primary objective, 235 
efficacy against RSV-associated respiratory illness between 14 days post 236 
vaccination throughout the end of the surveillance period, approximately 7 237 
months. MEDI-7510 was a subunit vaccine using soluble (unaggregated) 238 
postfusion (post-F) conformation of the F protein with a TLR4 agonist 239 
adjuvant. that The vaccine candidate showed safety and immunogenicity with 240 
elevated increased B and T cell responses in the vaccine group compared to 241 
the placebo group in a phase I clinical trials(47) after safety and improved 242 
immunogenicity with an adjuvant was demonstrated in a first-in-human 243 
trial(48). The incidence of RSV-associated ARI respiratory illness as diagnosed 244 
by PCR was 1.7% and 1.6% in the vaccine and placebo groups respectively, for 245 
a vaccine efficacy (VE) of -7.1(47). No efficacy was found in secondary subset 246 
analyses. On day 29, 93% of vaccinees had an anti-F IgG antibody 247 
seroresponse and there was a 4.6 geometric mean fold rise in anti-F IgG titer at 248 
the end of the RSV season in vaccine recipients compared to the placebo 249 
group(47).  One proposed explanation for the negative results may be that the 250 
choice of a post-F antigen induced antibodies without appropriate epitope 251 
specificity(49). Upon further analysis, other proposed explanations include a 252 
low incidence of laboratory-confirmed RSV in the study population, or a 253 
selection of the study population, which included high-risk and low-risk older 254 
adults. Considerations for the future include selection of an older study 255 
population at higher risk of RSV infection. 256 
 257 
Vaccine antigens 258 
Vaccine antigens included in RSV vaccine candidates are diverse. The majority of 259 
vaccines in clinical trials (11/18) utilize use the F protein, a class I viral fusion 260 
protein, as an antigenic target. The RSV F protein is highly conserved and facilitates 261 
viral fusion with host cells. An uUnderstanding of the structural differences between 262 
pre-F and post-F conformations, as well as stabilization of the pre-F soluble forms, 263 
has resulted in advancesment in vaccine antigen design(19,50). Current vaccine 264 
candidatess use pre-F and post-F as vaccine antigens [Table 1]. Of note, the 265 
predominant conformation displayed on the FI-RSV vaccine candidate was the post-266 
F conformation(51).  There is no consensus on theIt remains unclear as to whether 267 
there is a trigger for the pre-F to post-F conformational change, but it does occur 268 
spontaneously, making it difficult to ensure that a wild-type F vaccine antigen 269 
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maintains a pre-F conformation. However,, but stabilizing mutations have been 270 
identified that can preserve the pre-F-specific epitopes(50,52). The antigenicity of 271 
some stabilized pre-F constructs has not been rigorously investigated, and it 272 
remains an open question as to whether certain stabilizing mutations affect the 273 
conformation of antibody binding sites Assays to assess antigen conformation are 274 
needed. Likewise there is no consensus on cellular receptors that determine viral 275 
tropism(53).  276 
 Other less frequently utilized vaccine antigens, used alone or in combination 277 
with other antigens in vaccine candidates, include the RSV envelope associated 278 
glycoproteins G (1/18) and small hydrophobic (SH) protein (SH) (1/18) as well as 279 
internal proteins: nucleocapsid (N) (3/18), M (1/18), and M2-1 (1/18). Other 280 
thanBesides the F protein, the G protein is the only other target for neutralizing 281 
antibodies on the viral surface. The G protein is most important for viral attachment 282 
of RSV and is less frequently utilized as a vaccine antigen due to high variability 283 
across RSV strains(54), and limited knowledge of its surface structure(55). The G 284 
protein exists as an oligomer on the surface of RSV particles and as a monomer 285 
when secreted from infected cells as ain soluble form(56). There is evidence that the 286 
soluble form of the G protein can act as a decoy that helps the virus evade the 287 
antibody response(57). Another possible vaccine target, the SH protein, is not well 288 
understood, but has been observeddata suggest that it to plays a role in viral 289 
replication in vivo(53) and inflammasome activation(58). The SH protein contains a 290 
transmembrane and extracellular domains(59); the latter has been used as a 291 
vaccine antigen(60). Internal proteins are particularly relevant to induce T cell-292 
mediated immunity(55). As such, three non-membrane RSV proteins have been 293 
included in RSV vaccine design. The N protein is the major nucleocapsid protein that 294 
encapsidates the RNA genome of the virus(61). The M2-1 and M2-2 proteins are 295 
specific to RSV and other Pneumoviridae. M2-1 is an essential protein for viral 296 
transcription (62), and deletion of M2-2 deletion is utilized in live vaccine 297 
candidates for viral attenuation. Finally, the M protein is a membrane-associated 298 
protein which is important for formation of the viral envelopethat gives virions their 299 
filamentous shape(63,64). In summary, different viral proteins are being employed 300 
as antigens in RSV vaccine design. Viral surface glycoproteins such as F and G are 301 
known to induce antibodies with differing neutralization capacity. The SH protein 302 
may be important for induction of antibody dependent cell-mediated cytotoxicity 303 
(ADCC), whereas non-membrane proteins are especially important to induce a 304 
robust T- cell response(55). 305 
 306 
Target populations 307 
RSV prophylactic interventions are designed to protect at least two populations 308 
most vulnerable to severe RSV disease: RSV-naïve young infants and children, and 309 
older adults, although other important high-risk populations are important to 310 
consider. It is estimated that 45% of hospital admissions and in-hospital deaths due 311 
to RSV-ALRI occur in infants younger than 6 months of age(1), an age at which 312 
vaccines are generally less immunogenic. Older adults and adults with chronic 313 
cardiopulmonary conditions have emerged as an important target for RSV 314 
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prevention due to an increased understanding of RSV burden in this population. An 315 
overview of all RSV vaccine candidates per target population is shown in Table 2. 316 
Maternal vaccination is utilized to provide passive immunity to young infants 317 
by boosting maternal vaccine-specific antibody titers that are actively transferred 318 
through the placentato the infant, thereby extending the period of protection 319 
conferred by maternal antibodies. Historically, epidemiologic studies have 320 
demonstrated an association between higher maternal RSV antibody concentrations 321 
and protection from lower respiratory tract infectionALRI in infants(65). Passive 322 
transfer of antibodies to infants has been shown to be protective against severe RSV 323 
infection through the administration of high-titer polyclonal and monoclonal 324 
antibodies (RSV-IVIG and palivizumab) (28,29). The duration of protection of 325 
maternal vaccination is defined by the antibody half-life. Administration of mAbs is 326 
an alternative form of passive vaccination that can circumvent this hurdle due to 327 
extended antibody half-life through Fc alterations(66).  The proof-of-principle of 328 
maternal vaccination as a tool to prevent infant disease has been demonstrated by 329 
the effective near-elimination of maternal and neonatal tetanus worldwide through 330 
tetanus toxoid vaccination in pregnancy(67).  Maternal vaccination may also play a 331 
role in prevention ofpreventing RSV infection in pregnant women and prevention of 332 
adverse birth outcomes, however data on the burden of RSV disease in pregnant 333 
women and the effect of RSV infection during pregnancy on the fetus is limited(68–334 
71)  335 
 Premature infants, a population at high risk for severe RSV disease, may be 336 
insufficiently protected by maternal vaccination given that the majority of IgG 337 
transport of IgG occurs after 32 weeks gestational age(72). Globally 10% of children 338 
are born preterm(73). The burden is especially relevant in low and middle-income 339 
countries (LMICs) as more than 60% of preterm birth occurs in Sub-Saharan Africa 340 
and South Asia(74). Thus, a maternal vaccination strategy may not be sufficient to 341 
protect the high-risk preterm population if administered during the third trimester 342 
of pregnancy. Tetanus- diphtheria- acellular pertussis (Tdap) immunization in the 343 
second trimester is associated with higher cord-blood antibody titers by time of 344 
birth as compared to third trimester immunization(75). A strategy of earlier 345 
vaccination could be considered for maternal RSV immunization to maximize 346 
protection forto preterm infants. Other populations in which impaired 347 
transplacental antibody transfer may limit protection by maternal vaccination 348 
include infants of mothers with chronic infection, hypergammaglobulinaemia, 349 
malaria, and HIV infection(76). The ratio of transplacental antibody transfer and 350 
antibody decay kinetics are currently considered the main parameters to assess 351 
protection conferred via maternal vaccination. However, protection may also be 352 
mediated by breast milk antibodies transferred postnatally.  353 
 A combined strategy that utilizes maternal passive vaccination immunization 354 
to protect young infants, via maternal vaccination or mAbs,  followed by pediatric 355 
active vaccination immunization may be effective to prevent severe RSV infection in 356 
young children(77). The combinedis strategy is estimated to avert at least twice as 357 
many admissions per 100 births and four times as many in-hospital deaths per 1000 358 
births than maternal vaccination alone(77). A combinedThis strategy will be 359 
particularly relevant to prevent morbidity and mortality in children with 360 
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comorbidities who are at risk of severe RSV disease at older ages (78,79). A similar 361 
maternal and pediatric combined passive and active immunization strategy is 362 
currently employed for pertussis and influenza vaccination(76).  363 
 Although RSV is frequently considered a pediatric pathogen, it is important 364 
to consider the older adult population with regard to prevention of severe RSV 365 
disease. RSV has been identified as an important disease in older and high-risk 366 
adults, with a disease burden similar to that of influenza(3). It is estimated that RSV 367 
accounts for 10,000 – 14,000 deaths annually in adults over the age of 65 years in 368 
the United StatesUS(2,3). In addition, older adults with comorbidities such as 369 
underlying heart or lung disease are at elevated risk of severe RSV disease; 4-10% of 370 
high-risk adults will develop acute RSV infection annually(3). 371 
 372 
Immunologic endpoints 373 
Antibodies are thought to be the key players in limiting RSV ALRI as evidenced by 374 
proven protection in immunoprophylaxis trials in children (28,29,33). Recent 375 
evidence from experimental human infection in adults shows a protective role for 376 
nasal RSV-specific IgA against RSV infection(6), underscoring the importance of 377 
mucosal immunity. A limited ability to generate memory IgA responses after RSV 378 
infection may be in part responsible for incomplete immunity and subsequent RSV 379 
re-infection. Antibodies directed against different antigenic sites of the F protein 380 
display different neutralization capacities with the most neutralization-sensitive 381 
epitopes exclusive to the pre-F conformation. Antibodies with specificity for 382 
antigenic sites Ø and V show high neutralizing activity and are exclusive to the pre-F 383 
conformation(41,80). Antigenic site Ø is located at the apex of the pre-F 384 
conformation, the most variable region of the highly conserved F protein(19). 385 
Antibodies against antigenic site III prefer the pre-F conformation and exhibit high 386 
neutralizing activity(81). Antibodies directed against site II and IV, present on both 387 
pre-F and post-F, exhibit medium to high neutralization potency(80,82). Finally, 388 
antibodies against antigenic site I, present primarily on post-F, show weak or no 389 
neutralization. Escape mutants of these antigenic sites have been identified, but 390 
global RSV genetic data are needed to assess the molecular heterogeneity of RSV 391 
and the subsequent susceptibility or resistance to mAbs targeting RSV among 392 
circulating viruses.  393 
 The mechanisms of protection may differ according to the type of 394 
vaccinevaccine type, and therefore, many different immunologic assays are 395 
employed in clinical trials. Neutralizing activity of serum is a frequent immunologic 396 
endpoint of vaccine trials. A measure of functional antibody response can be 397 
elucidated by the ratio of fold-increase in RSV-binding antibodies to fold-increase in 398 
RSV-neutralizing antibodies (ELISA-to-neutralization response ratio). A ratio of <1 399 
may be an important correlate of protection(83). Furthermore, rather than a 400 
definitive protective threshold for antibodies, fold-rise in antibody titer may be a 401 
relevant correlate of protection for live-attenuated vaccines, since that may be the 402 
best indicator of B- cell priming. Recent efforts by PATH, the WHO, and the National 403 
Institute for Biological Standards and Control (NIBSC) examined the variability of 404 
RSV neutralization assays across laboratories and recommended steps for improved 405 
standardization globally(84), resulting in the development of a new WHO 406 
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International Standard for Antiserum to RSV with 1000 International Units of RSV 407 
subtype A neutralizing activity per vial now available through the NIBSC(85). For 408 
otherStandardization of other frequently used immunologic assays such as 409 
palivizumab-competing antibodies (PCA), ELISA and T- cell assays such 410 
standardization has not yet taken place. 411 
 Once infection of the lower airways is established, CD8 T- cells play an 412 
important role in viral clearance(86). Th2-biased responses have been associated 413 
with animal models of RSV ERD and measurement of Th1 and Th2 responses are 414 
considered important to predict safety of vaccine candidates other than live-415 
attenuated vaccines in clinical trials in young children.  416 
 Animal models are important for preclinical development of vaccine 417 
candidates and assessing the possibility of enhanced disease. Alveolitis in the cotton 418 
rat and priming of a Th2 response in mice are considered markers to assess possible 419 
ERD; there is no consensus on the ability to reproduce ERD in calves(87).  420 
 Although we discuss several potential immunological correlates of protection 421 
for vaccine trials, we considered cell-mediated immunity beyond the scope of the 422 
manuscript. However, wWe highlight the different aspects of the expected immune 423 
response for all 19 vaccine candidates and mAbs in clinical development in Table 3. 424 
A definitive threshold for protection against RSV disease remains elusive. So far no 425 
vaccine candidates have been tested in the experimental human infection model, but 426 
the model provides a unique opportunity to test vaccine candidates in the natural 427 
host despite practical and ethical challenges(88).Ultimately, the outcome of large-428 
scale vaccine trials will inform which immunologic measures correspond to 429 
protection from clinical RSV disease. 430 
 431 
Vaccine strategies 432 
We have divided vaccines in clinical development into four categories in accordance 433 
with the PATH RSV vaccine and mAb snapshot: particle-based, vector-based, subunit 434 
and live-attenuated/chimeric vaccines(21). We have also included mAbs in clinical 435 
development for the prevention of RSV ALRI. In the snapshot there are 43 vaccines 436 
and 4 mAbs in development of which 19 are in clinical stage development. An 437 
important consideration for all vaccines is not only to prevent severe RSV disease, 438 
but also to avoid the risk of priming for RSV ERD. Based on our current 439 
understanding of the underlying mechanisms leading to RSV ERD, this would 440 
suggest caution should be taken in the use of protein-based vaccines in RSV naïve 441 
infants and childrenindividuals. Replication deficient vectors, engineered to induce 442 
CD8 T cell responses expressing RSV antigens intracellularly, are considered more 443 
similar to live-attenuated virus vaccines which have been shown to be safenot to 444 
cause ERD in this population. In Table 1 we provide a comprehensive overview and 445 
more detailed comparison of all characteristics of the 19 vaccine candidates and 446 
mAbs in clinical development. 447 
 448 
Particle-based vaccines 449 
The RSV F nanoparticle-based vaccine platform is currently being evaluated for 450 
protection of three target populations: (1) infants through maternal vaccination, (2) 451 
children between 6 months and 5 years, and (3) older adults. These vaccine 452 
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candidates utilize aggregates of a modified stabilized F protein which exhibits the 453 
post-F morphology(89). The maternal RSV F nanoparticle vaccine candidate is 454 
farthest along in clinical development and the PREPARE trial has entered the third 455 
year of a phase III trial to enroll up to 8,618 pregnant women at 80 sites in 11 456 
countries(43). In January 2018 an informational analysis of the phase III trial was 457 
announced in which the vaccine candidate successfully targeted an efficacy 458 
threshold against the primary endpoint in infants at day 90 of >40%(90). Second in 459 
clinical development is the RSV F nanoparticle vaccine for older adults. Despite lack 460 
of efficacy in a phase III trial (RESOLVE) with a non-adjuvanted vaccine candidate, 461 
development was continued in a phase II roll-over study initiated in January 2017 in 462 
Australia in 300 adults. The aim of this rollover trial is to determine whether 2 dose 463 
regimens with an adjuvant (Matrix-M, a saponin-based adjuvant, or aluminum-464 
phosphate) may increase the magnitude and quality of the immune response in this 465 
population. The results from the RESOLVE trial in older adults suggested vaccine 466 
efficacy in adults with COPD, leading to considerations to initiate a future trial in this 467 
older adult population at high risk for severe RSV infection(43). Finally, the phase I 468 
trial was completed in young children 24-72 months of age in 2016, but no data 469 
have been published yet(91). 470 
SynGEM is a particle-based needle-free vaccine candidate containing the RSV 471 
F protein attached to empty bacterial particles made from Lactococcus lactis. The In 472 
this vaccine platform an in which an antigen is presented by a bacterial particle. An 473 
influenza vaccine candidate in clinical trials which uses the same vaccine platform, 474 
has shown both local and systemic antibody responses for the influenza candidate in 475 
clinical trials using the same platform(92) but needs further optimization for RSV 476 
vaccination. The preliminary results of immunogenicity testing have been reported. 477 
The immunogenicity of this vaccine was evaluated after delivery as a nasal spray to 478 
healthy adult volunteers. Two intranasal doses of SynGEM were administered 28 479 
days apart at low or high dose in 24 subjects per group (6 subjects in each group 480 
receiving placebo, double blinded). Assays of serum virus neutralization, RSV F-481 
specific antibodies, palivizumab-competing antibodiesPCA, and F-specific IgA 482 
indicated some immunogenicity, but the results did not reach the threshold set for 483 
continuation to viral challenge and the studies were suspended in 2017 (Openshaw 484 
and Chiu, personal communication). 485 
 486 
Vector-based vaccines 487 
There are five vector-based vaccines in clinical development. The first uses a 488 
modified vaccinia virus Ankara (MVA), a replication-defective smallpox viral vector, 489 
and the remaining four vaccine candidates employ an adenovirus vector to display 490 
viral antigens. The MVA vector has been safely used in vaccines for other infectious 491 
diseases(93). This vaccine candidate, MVA-BN-RSV, induces both a humoral and 492 
cell-mediated responses by displaying four vaccine antigens: F, G, N and M2-1. Phase 493 
II results in healthy older adults from this candidate will soon be announced.  494 
 The second vector-based vaccine candidate, VXA-RSV-f, uses an innovative 495 
platform with an adenovirus 5 based oral tablet delivery platform that is stable at 496 
room temperature. Using the same oral adenovirus vaccine delivery platform, a 497 
phase I trial for influenza has been conducted, which showed neutralizing antibody 498 
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responses against influenza and no interference of pre-existing vector 499 
immunity(94). The results from Ppreclinical studies for the RSV vaccine candidate in 500 
the cotton rat model showed that mucosal immunization with the oral vaccine 501 
candidate enhanced mucosal IgA in the upper airwaysan increase in anti-F 502 
antibodies and protection against RSV challenge(95). Given that severe disease iIn 503 
the older adult population  is thought to be mediated by immunosenescence may be 504 
characterized by impaired T- cell responses to RSV(96,97). , Tthis vaccine candidate, 505 
which induces a humoral response, may be a promising intervention in this 506 
population. for the older adult population(98). 507 
 Third and fourth, Ad26.RSV.preF, is a vaccine candidate being developed for 508 
two populations: the older adult and the pediatric population. In thisThe candidate 509 
uses pre-F antigen is expressed in the human adenovirus strain 26, a vector with a 510 
favorable safety profile when used for other infectious diseases(98,99). Previously, 511 
the vaccine candidate vector expressed post-F as antigen (FA2) but has now been 512 
changed to the stabilized pre-F conformation as vaccine antigen. The stabilized pre-513 
F protein has 5 amino acid changes from wild-type, and is stable at 4C and heat-514 
stable(50). With the expectation that this vaccine candidate will induce highly 515 
neutralizing antibodies against pre-F, phase II trials will be initiated conducted in 516 
RSV-seropositive children. In December 2017 a phase II trial has beenwas initiated 517 
comparing concomitant administration of influenza vaccination with RSV vaccine 518 
and seasonal influenza vaccine versus seasonal influenza vaccine alone co-519 
administration in healthy older adults(100). 520 
 Fifth, ChAd155-RSV, a replication-incompetent chimpanzee adenovirus 155 521 
has been used as a vector for the F, N and M2.1 proteins. The anticipated use for this 522 
pediatric vaccine is to start immunization at two months of age, and to use two to 523 
three doses alongside the normal pediatric vaccination schedule, instead of 524 
seasonally(101). This vaccine candidate is currently being evaluated in 12-23 month 525 
old RSV seropositive children. In the future, there are plans to conduct clinical trials 526 
in seronegative children sequentially from older to younger ages (12-24 months 527 
followed by 6-12 months and subsequently 2-6 months of age) to ensure safety in 528 
RSV-naïve populations. Results of phase II trials are expected to be announced in 529 
2020.  530 
In summary, vector-based vaccines are used to display various RSV viral 531 
proteins and three of these vaccine candidates are in phase II trials. 532 
 533 
Subunit vaccines 534 
Due to concerns of ERD associated with protein-based vaccines, subunit vaccines 535 
are only in development for pregnant women and older adult populations. One 536 
subunit vaccine in development is the GSK RSV F vaccine candidate, which uses a 537 
version of soluble secreted F protein empirically engineered to maintain the Pre-F 538 
conformation. Phase I results demonstrated safety and immunogenicity as 539 
evidenced by RSV neutralizing antibody response in healthy men(102). However, a 540 
phase II trial scheduled for 2017 was halted due to instability of the pre-F antigen 541 
during manufacturing. 542 
 Structure-guided stabilization of the pre-F conformation has yielded a 543 
subunit vaccine candidate, DS-Cav1. The stabilization includes a foldon 544 
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trimerization domain, the introduction of cysteine residues to form a disulfide bond, 545 
and cavity-filling hydrophobic residues(52). The vaccine is able to preserve 546 
neutralization-sensitive epitopes on a functional pre-F form of the viral surface 547 
protein. In preclinical studies the subunit vaccine induced high levels of RSV-548 
neutralizing antibodies in mice and non-human primates(52). Preliminary results 549 
from the phase I trial, VRC 317, are promising and will soon be published. are 550 
expected to be published soon. 551 
 DPX-RSV is a vaccine candidate with a unique choice of vaccine antigen;, the 552 
extracellular domain of the SH protein of RSV(60). The DepoVax technology allows 553 
for a prolonged exposure of antigen and adjuvant, and aims to induce ADCC using a 554 
liposome and oil-based depot(103). The antigen and adjuvant are encapsulated in a 555 
liposome, lyophilized and suspended in oil and the process is expected to produce 556 
vaccines with long shelf-life stability(104). Phase I results on safety and 557 
immunogenicity in the older adult population will soonhave been released and are 558 
expected to be  be published from thisan investigator-initiated study. 559 
 560 
Live-attenuated and chimeric vaccines 561 
In the context of historical concerns for enhanced RSV disease, live-attenuated 562 
vaccines can be considered safe for RSV naïve infants, based on consistent clinical 563 
study results showing that these candidates do not prime for ERD following 564 
subsequent exposure to wild-type RSV after vaccination(105). Another benefit of 565 
live-attenuated vaccines against RSV in the pediatric population young infants is 566 
their ability to generate an immune responsereplicate in the respiratory tract 567 
despite the presence of maternally-acquired antibodies, and to elicit a more broad 568 
antibody humoral and cellular response(106). Live-attenuated vaccines are likely 569 
limited to the pediatric population under two years of age, as pre-existing immunity 570 
in older populations might not permit sufficient replication to generate protective 571 
immune responses. Safety could be a concern for intranasal live-attenuated vaccines, 572 
in particular if attenuation is insufficient. However, evaluation of current vaccines 573 
has not shown evidence of increased rates of vaccine-associated ALRI or fever, 574 
though there may be increased rates of rhinorrhea, similar to what has been 575 
observed with the live-attenuated influenza vaccines. 576 
 Five live-attenuated vaccine candidates in phase I clinical trials are being 577 
developed in partnership with the National Institutes of Health (NIH).  Live-578 
attenuated vaccines face the challenge of achieving sufficient attenuation to be safe 579 
while remaining immunogenic enough to induce a protective immune response., but 580 
An iimproved understanding of the RSV viral genome has informed the development 581 
of new vaccine candidates that may overcome this challenge. Two main 582 
modifications to the RSV genome have been engineered through reverse genetics: 583 
the ΔM2-2 deletion which attenuates viral replication and upregulates antigen 584 
expression(37) as well as the ΔNS2 deletion which reduces viral suppression of host 585 
interferon thereby boosting the innate immune response. RSV MEDI ΔM2-2 strongly 586 
reduced viral replication while inducing a strong primary serum neutralizing 587 
antibody as well as potent anamnestic response in RSV-seronegative infants and 588 
children(37). Further results from phase I clinical trials with the other live-589 
attenuated vaccine candidatess are expected. 590 
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The only chimeric vaccine candidate, rBCG-N-hRSV, currently in clinical 591 
development is delivered via a BCG strain. BCG has a safe profile in newborns and 592 
infants, induces a Th1 response(107,108), and allows for combined vaccination 593 
against two major respiratory pathogens: Mycobacterium tuberculosis and RSV. Not 594 
only is the Th1 cellular response important in protecting against lung pathology, 595 
inflammation and viral replication(109) but the candidate also induces a humoral 596 
response. The antigen presented by this vaccine candidate is the RSV N protein(110). 597 
ImportantlyPresently, this candidate is the only vaccine candidate intended for 598 
administration to newborn infants(110). 599 
 600 
Monoclonal antibodies 601 
A promising highly potent monoclonal antibody has emerged as a passive 602 
administration strategy to prevent severe RSV infection. MEDI8897, also known as 603 
nirsevimab, was optimized from the human antibody D25 that targets antigenic site 604 
Ø on the pre-F conformation, which is more neutralization sensitive than the 605 
palivizumab epitope, antigenic site II. Using the YTE technology for extendingwhich 606 
extends antibody half-life as well as modulates ADCC(111), the three-fold increase 607 
in half-life of MEDI8897(112) compared to palivizumab offers the possibility of 608 
passive protection for all infants for an entire season through a single intramuscular 609 
injection. The intended use is for both term and preterm infants entering their first 610 
RSV season. Passive vaccination with an extended half-life antibody offers an 611 
approach to protecting infants that is safe and may be reasonably priced. 612 
Representatives of the pharmaceutical company have indicated that they expect 613 
vaccine-like pricing of for MEDI8897. Given the increased potency, the extended 614 
half-life, and the required dose, it is expected that the cost to protect an infant 615 
during the RSV season can be kept relatively low(66). 616 
 617 
Other approaches not in clinical development 618 
Other emerging approaches not yet in clinical development include nucleic acid-619 
based vaccines(113). Importantly these vaccines induce a T- cell response 620 
mimicking the response to live virus infection. Both DNA and messenger RNA 621 
(mRNA) vaccines against RSV have shown promising results in preclinical 622 
studies(113). Notably, through a collaboration with the Bill & Melinda Gates 623 
Foundation, an mRNA technology vaccine platform for HIV and rotavirus has also 624 
expanded to include RSV. Another vaccine approach in preclinical development is a 625 
whole-inactivated vaccine to be delivered intranasally via a nanoemulsion 626 
technology, for which development has been supported by the Bill & Melinda Gates 627 
Foundation(114). Furthermore, with the first of the palivizumab patents expiring in 628 
October 2015 and the last in 2022, there has been active development to produce a 629 
biosimilar in order to provide a low-cost RSV preventive intervention. . 630 
 631 
Considerations by regulatory agencies and the World Health Organization 632 
The FDA has articulated that differences between high income countries (HICs) and 633 
LMICs are not particularly relevant to regulatory decisions, though a bridging study 634 
in the US must be performed if all clinical trials have been performed outside of the 635 
US(115). The EMA does not require that trials intended to support a regulatory 636 
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decision are conducted in the European Union. Other considerations in population 637 
selection for vaccine trials mentioned by EMA include: first testing a vaccine 638 
candidate in a seropositive before testing in a seronegative population, testing a 639 
maternal vaccine in non-pregnant women of child-bearing age before testing in 640 
pregnant women, and including older adults with comorbidities in vaccine trials. No 641 
particular considerations were mentioned for population selection in studies for 642 
mAbs. In October 2017 the EMA released draft guidelines for the clinical evaluation 643 
of RSV prophylactic interventions which included guidance regarding trial design, 644 
assessment of efficacy, and safety(116). The draft guidelines will be revised after a 645 
period of public consultation based on comments and new publications. 646 
 The WHO has recognized the importance of RSV as a global health problem 647 
and has identified the development of RSV vaccines as a priority for the WHO 648 
Initiative for Vaccine Research and for Biological Standardization. WHO recently 649 
developed RSV vaccines preferred product characteristics and research and 650 
development technical roadmap documents(117,118). Further guidance for 651 
development will contribute to adequate policy-making. WHO standardization 652 
activities led to the development and establishment of the first international 653 
standard for antiserum to RSV. Development of guidelines for evaluation of quality, 654 
safety and efficacy of RSV vaccines has been initiated and will be part of consultation 655 
with regulators, manufacturers and academia in 2018 with the aim of finalizing it in 656 
2019. Further discussion on guiding principles for mAbs is needed before 657 
proceeding with the development of the WHO Guidelines. These and other WHO 658 
standards serve as a basis for setting national regulatory requirements as well as 659 
WHO prequalification.  660 
Finally, the WHO is now performing a surveillance pilot study in 14 countries 661 
to test the feasibility of using the Global Influenza Surveillance and Response System 662 
platform for RSV surveillance and it is expected that this pilot will contribute to our 663 
understanding of the RSV disease burden and seasonality in different geographical 664 
regions(119). 665 
 666 
Discussion   667 
Challenges in RSV vaccine design include concerns of ERD post-vaccination, lack of 668 
definitive immunologic correlates of protection, lack of consensus regarding clinical 669 
endpoints, and limited natural immunity following RSV infection. Despite these 670 
challenges, recent developments such as an understanding of the structural biology 671 
of the RSV fusion protein as well as lessons learned from late-phase vaccine trial 672 
failures have informed the field as it moves forward.  673 
We attempted to collect data regarding expected plans for access to a 674 
preventive intervention in LMICs and expected pricing for all vaccine candidates, 675 
however this information iwas not publicly available. The only information obtained 676 
regarding expected pricing was for MEDI8897, though a more specific estimate than 677 
vaccine-like pricing was not available. Given that the most severe RSV infection 678 
occurs in LMICs(17), information regarding LMIC target countries and potential 679 
pricing for vaccine candidates will be essential to facilitate access to vaccines 680 
worldwide, especially in areas where the mortality burden is highest. In LMICs the 681 
most important target for vaccine candidates is young children(120). A mechanism 682 
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should be introduced to ensure that information regarding expected pricing and 683 
access to interventions is transparent and available in the public domain. RSV 684 
vaccines and mAbs will be considered in the development of the Vaccine Investment 685 
Strategy (VIS) by GAVI, the Vaccine Alliance in 2018(121).  686 
A vaccine trial may be considered a probe study to determine whether a 687 
causal relationship exists between RSV infection and asthma, a longstanding 688 
question in the field. If long-term follow-up had been undertaken during the pivotal 689 
RSV prevention trials using palivizumab, these trials would now have provided 20 690 
years of follow-up on respiratory morbidity after RSV prevention in high-risk 691 
infants. Lack of long-term surveillance for airway morbidity in vaccine trials are 692 
missed opportunities to provide novel scientific insights important not only to 693 
understand the pathophysiology pathogenesis but also the long-term vaccine 694 
efficacy against airway morbidity following RSV infection. In addition to wheeze, 695 
objective outcomes, such as lung function measurements including demonstration 696 
of bronchial hyperreactivity and IgE measurements will ideally be incorporated in 697 
vaccine trials to fully understand the impact of RSV prevention on asthma 698 
development.  699 
 Viral interference, in which RSV inhibits infection by other viruses, is 700 
becoming an increasingly important concept to understand in the context of an 701 
approved RSV vaccine. RSV vaccination may conceivably result in an increased or 702 
decreased prevalence of other respiratory viruses. There is evidence supporting 703 
viral interference for influenza vaccination(122,123), for RSV prevention(124,125), 704 
and during the RSV season in the absence of RSV (126). It is important for vaccine 705 
trials to examine this phenomenon by evaluating the incidence of all-cause ALRI, as 706 
well as RSV-specific ALRI, to better understand the implications of viral interference 707 
for an RSV vaccine. 708 
 This review provides an extensive overview of the 19 vaccine candidates and 709 
mAbs in clinical trials to prevent RSV infection.  RSV vaccine development is moving 710 
rapidly and shows promise to address an unmet global health problem. Vaccines for 711 
various target populations are in clinical development. One vaccine candidate and 712 
one mAb are in late phase trials (IIb/III) and aim to prevent the disease burden in 713 
young infants. Despite some recent failures, RSV vaccine candidates and mAbs, in 714 
clinical development hold the promise that a preventive intervention for RSV is on 715 
the horizon. 716 
 717 
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PhII: safe, VE: 41% 
against RSV-ARD, 64% 
VE against RSV-msLRTD(135) 
 
PhIII: safe, no efficacy v. 
RSV-ARD &RSV-msLRTD;; post- 




PhII rollover: no residual  
protection in 2nd year; 
second immunization protective 
against RSV-ARD and msLRTD 
 (n=1329)(131,136) 




























N/A N/A PhI: well-tolerates;; 
Anti-F IgG & PCA increase d14, 
Peak d28, elevated to d56; 
10-fold increase  
PCA & anti-F IgA adjuvanted  
6-fold increase 














BLP BLP allows 
presentation 
of F protein 
and elicits 
mucosal IgA 







N/A N/A PhI: some immunogenicity 
in healthy adults but did not 
meet threshold; development 
suspended. 
VECTOR-BASED 
















blocked at a 
late stage 























N/A PhI; safe, 2x increase 
IgG & IgA; 3-5x increase 
In T cell responses 
(n=63)(137) 
 
PhII interim results:  
well-tolerated; broad Ab & T 
cell response in older adults 



















directly to gut  
(ileum) 






2018? N/A Preclinical:  Systemic 
Anti-F Ab’s  and protection 





































N/A PhI: well-tolerated; durable 
humoral and cellular immune 
response for FA2 candidate; 
comparable or higher for preF 






































ChAd155-RSV GSK Chimpanzee 
adenovirus 
ChAd155-RSV 


































PhI: safe, B cell and RSV- 
neutralizing antibodies 
in RSV-seropositive  
adults (n=73)(141) 
SUBUNIT              
GSK RSV F GSK Pre-F 
produced in 
CHO cells 
































































N/A PhI: safe, RSV-A neutralizing 
Ab titers increased 3.2-4.9x; 
remained high to day 60,  
decreased on day 180 & 360 
in healthy men (n=128)(102) 
 
Ph II:  Increased RSV-A 
neutralizing Ab  30 days 
post-vaccination in  

































N/A N/A PhI: Well-tolerated, 
Antigen-specific Ab response 
durable to day 421, 
low immunogenicity with  
alum adjuvant 
in healthy older adults(143) 
















N/A N/A Preclinical: Induction of high 
neutralizing Abs and 
differential adjuvant-induced  
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expressed in 












Immunization of mice and  
macaques induces RSV- 
























N/A N/A Preclinical: Protective T cell 
immune response and  









genetics and  
5 aa 
substitutions 
in 3 proteins 
called the “cp” 
mutations, 
originally 





























N/A N/A N/A 
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N/A N/A N/A 




























N/A N/A N/A 
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MONOCLONAL ANTIBODY (mAb) 




mutation in Fc 
N/A N/A Antibody 
targeting site 
Ø of the F 
protein of 
RSV with an 
extended 
half-life 
























N/A PhI; well-tolerated,, 
Mean half-life 85-117d; 
time to max concentration  
5-9 days; bioavailability 77% 
in healthy adults (n=136) 
(146) 
      
 
        
 
Legend: N/A: not applicable or not available, IM: intramuscular, ID: intradermal, IN: intranasal, IV: intravenous; ARD: acute 
respiratory disease, PCA: palivizumab-competing antibodies, P: pediatric, M: maternal, O: older adults, SHe: small hydrophobic 
protein ectodomiain; RSV ARD: all symptomatic respiratory disease due to RSV; msLRTD: moderate-severe RSV-associated 
lower respiratory tract disease; NIAID: National Institutes of Allergy and Infectious Diseases; VRC: Vaccine Research Center; 




Table 2 Overview of vaccines and mAbs by target population 
 
Target Population Vaccine Vaccine type 
Pregnant mothers   
Third trimester RSV F nanoparticle 
(Novavax) 
Nanoparticle 
Third trimester RSV F 
(GSK) 
Subunit 
 RSV F protein (NIH/NIAID/VRC) Subunit 
Pediatric   
6m-5y RSV F nanoparticle 
(Novavax) 
Nanoparticle 
Start 2m Adenovirus 
(GSK) 
Vector 




(Pontificia Unversidad Catolica de 
Chile) 
Chimeric 
 RSV D46 cp ΔM2-2  
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV LID ΔM2-2 1030s  
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV ΔNS2 Δ1313 I1314L 
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV D46/NS2/ N/ΔM2-2-HindIII 
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 






Older adults   
 RSV F nanoparticle 
(Novavax) 
Nanoparticle 
 RSV BLP 
(Mucosis) 
Nanoparticle 
 MVA (Bavarian Nordic) Vector 
 Adenovirus (Vaxart) Vector 
 Adenovirus (Janssen) Vector 
 DPX-RSV-SH Protein 
(Immunovaccine) 
Subunit 
 RSV F protein 
(NIH/NIAID/VRC) 
Subunit 
Legend: m: months; y: years
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Table 3: Expected immune response and previous successes for vaccine candidates and monoclonal antibodies 
 
Vaccine Target Population Pre-F Immunity* (86) Immune response Mucosal/Systemic 
Nanoparticle     
RSV F Nanoparticle 
(Novavax) 
M Pre-F < post-F Broadly neutralizing 
antibodies 
systemic 
RSV F Nanoparticle 
(Novavax) 
O Pre-F < post-F Broadly neutralizing 
antibodies 
systemic 
RSV F Nanoparticle 
(Novavax) 





O & P unclear F confirmation Activation of B & T cells; 
local secretion of 
neutralizing IgA in the 
nose; production of IgG 
neutralizing IgG in the 
blood 
mucosal & systemic 
Vector     
MVA 
(Bavarian Nordic) 
O Pre-F < post-F B & T cell response; 





O Pre-F > post-F B & T cell response; 
neutralizing antibodies 
against F antigen; CD8 T 
cells against F, N and 
M2.1 antigens 
systemic 
Adenovirus (Vaxart) O Pre-F < post-F B & T cell immunity, 
protection at mucosal 
surface 
mucosal > systemic 
Adenovirus (Janssen) P Pre-F B & T cells systemic 
Adenovirus (Janssen) O  Pre-F B & T cells systemic 
Subunit     
RSV F (GSK) M Pre-F B & T cell response systemic 
DPX-RSV (Dalhousie 
University) 
O none  systemic 
RSV F protein 
(NIH/NIAID/VRC) 
O & M Pre-F  systemic 
Live-attenuated     
BCG/RSV 
s(Pontificia Universidad 
Catolica de Chile) 
P Pre-F & post-F B & T cell response; Th1 
polarized response; 
antibodies against N, F, G 
systemic 
RSV D46 cp ΔM2-2 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response; 
enhanced antibody 
production due to 
increased antigen 
production from M2-2 
deletion 
mucosal & systemic 
RSV LID ΔM2-2 1030s 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response; 
enhanced antibody 
production due to 
increased antigen 
production from M2-2 
deletion 
mucosal & systemic 
RSV ΔNS2 Δ1313/I1314L 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response mucosal & systemic 
RSV D46 ΔNS2 N ΔM2-2 
HindIII 
P Pre-F & post-F B & T cell response; 
enhanced antibody 





production due to 
increased antigen 
production from M2-2 
deletion 
RSV LID cp ΔM2-2 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response; 
enhanced antibody 
production due to 
increased antigen 
production from M2-2 
deletion 
mucosal & systemic 
Monoclonal Antibody   
MEDI8897 
(MedImmune) 
P N/A N/A N/A 
 
Legend: Pre-F: prefusion conformation of the RSV F protein; Post-F: postfusion conformation of the RSV F protein; N: RSV 
nucleocapsid protein; F: RSV fusion protein; G: RSV attachment protein; O: older adults; M: maternal; P: pediatric. 
  
 42 
Figure 1: RSV global burden of disease in children under 5 years of age: key facts and figures   
 
 
Figure 1 Incidence is shown worldwide for children under 5 years of age unless otherwise stated. The hospital admission rate 
of 15.9 hospital admissions per 1000 neonates per year is in developing countries. The RSV ALRI hospitalization 63.9 among 
premature infants <1 year is reported per 1000 children per year globally. Legend: OR: odds ratio; LRTI: lower respiratory 
tract infection, RSV: respiratory syncytial virus, HIC: high income country, *: compared to children who survived RSV 
hospitalization and were mechanically ventilated. References: (a)(1) (b)(78) (c)(147) (d)(148) (e)(149) (f)(150)  
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Figure 2: Overview of Vaccine candidates and monoclonal antibodies in clinical trials per preventive approach including 




Legend: For vaccine candidate names listed in gray development has been halted since the last RSV therapeutics review 
performed in 2015(20). Abbreviations: PH I: phase I; PH II: phase II; PH III: phase III.  
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Response to comments 
 
Dear editor,  
 
We would like to thank you for the extensive comments, which have given us the chance 
to clarify and improve the manuscript. The manuscript has been revised addressing each 
of the recommended changes made by reviewers point-by-point. We hope the length of 
the manuscript is acceptable as we cover a broad range of issues related to RSV vaccine 
development. Actually, the reviewers encouraged us to expand on a few topics. Should 
you decide it needs shortening, we would welcome any editorial suggestion. 
 
Kind regards, 




Comment 1 [General]: Please be aware that the limit for the word count is 4500 words. 
Response: The current word count is 7,109 words. If the word count is absolute, we can 
consider moving part of the manuscript to supplemental materials. Please advise whether 
this is necessary. 
 
Comment 2 [General]: Please be aware that the limit for the number of references in 150. 
Response: We are aware of this limit and the manuscript currently contains 150 
references.  
 
Comment 3 [General]: Please include, at the end of the main text, a "Contributors" 
section detailing the role of each author in the preparation of your paper. 
Response: We moved the “authors contributions” to the end of the main text and renamed 
it “contributors.” 
 
Comment 4 [General]: Please include, at the end of the main text, a "Conflicts of interest" 
statement summarising key conflicts from the ICMJE forms. The standard wording, if 
there are no conflicts, is "We declare that we have no conflicts of interest." 
Response: We have summarized all relevant conflicts of interest in the manuscript using 
the conflict of interest forms sent in by all authors. 
Revised text: LJB and NIM were involved in the design and plan for this review. 
ACL and NH were involved in data collection. 
All authors contributed to the final manuscript. 
 
Comment 5 [General]: Please consider the possibility of having a study group name. 
When a paper includes a study group name in the byline, we're now required to supply a 
separate list of the group members in a specific format if we want these names to be 
shown on PubMed. (This is in addition to the list of names and affiliations required by 
the journal to be listed at the end of the paper or in the appendix.) 
To ensure that the information we supply to PubMed is accurate and complete, please 
email me a list of the study group members whose names should appear on PubMed in 
*Reply to Reviewers Comments
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Word table format, as follows: 
First names (will be abbreviated on Pubmed)Surnames (not abbreviated) 
David Villa Sanchez 
Jackie Henrietta                   Davidson 
This list will not be included in the paper itself - it's simply used to make sure that 
PubMed adds the names correctly. Please include the names of all study group members 
who need to be listed on PubMed. Names that do not need to be shown on PubMed do 
not need to be included. 
Response: We have added “on behalf of ReSViNET” as a study group. Please find the list 
of names to be shown on PubMed as you suggest. 
 
First names Surnames 
Natalie I Mazur 
Deborah Higgins 
Marta C Nunes 
José A. Melero* 
Annefleur C Langedijk 
Nicole Horsley 
Ursula J Buchholz 
Peter J Openshaw 
Jason S McLellan 
Janet A Englund 
Asuncion Mejias 
Ruth A Karron 
Eric AF Simões 
Ivana Knezevic 
Octavio Ramilo 
Pedro A Piedra 
Helen Y Chu 










Edward E Walsh 
Renato T Stein 
Barney S Graham 
Louis J Bont 
 
José Melero has passed away since the original submission of the manuscript. 
 3 
 
Comment 6 [General]: Please also include written consent of any cited individual(s) 
noted in acknowledgments or cited as personal communications.  
Response: We have obtained written consent from all individuals listed in the 
acknowledgments section and as personal communications. 
 
Comment 7 [General]: Reviews  should  include  a  brief  section  entitled  "Search 
 strategy  and  selection  criteria"  stating  the  sources  (including  databases,  MeSH  and 
 free  text  search  terms  and  filters,  and  reference  lists  from  journals or books) of the 
material covered, and the criteria used to  include  or  exclude  studies.  Citations to 
 papers  published  in  non-peer reviewed  supplements  are  discouraged.  Since  these 
 papers  should  be  comprehensive,  we  encourage  citation  of  publications  in  non-
English  languages. 
Response: Search strategy and selection criteria 
References for this review were identified through a search of PubMed for clinical trials 
with “syncytial” in the title published after January 1, 2013 with no language restrictions, 
through April 3, 2018. We did not intend to do a systematic review of the literature. No 
inclusion or exclusion criteria were used. Instead, we selected articles that were most 
relevant to the subheadings used in this review. The PATH RSV vaccine and mAb 
Snapshot was used as a reference to identify all vaccine and mAb candidates in clinical 
trials. ClinicalTrials.gov as well as the WHO vaccine pipeline tracker for RSV were used 
to identify all relevant trials for these vaccine candidates and mAbs. Additional data was 
collected during the RSV Vaccines for the World Conference on November 29- 
December 1, 2017 and through pharmaceutical websites for the respective vaccine and 
mAb candidates. 
 
Comment 8 [General]: Please ensure that you provide your figures in an editable format 
and as separate files. For trial profiles a word file made of editable text boxes is the 
preferred format. For any statistical images (histograms, survival or time-to-even curves, 
line graphs, scatter graphs, forest plots, etc) you should provide editable vector files (ie, 
the original artwork generated by the statistical package used to make the image). Our 
preferred formats for these files are .ai, .eps, or .pdf. We cannot guarantee accurate 
reproduction of images without these files.  
Response: We have sent all files in the correct format. 
 
General editorial points that apply to all pieces in the Green section (please check each 
point): 
 
Comment 9 [General]: Please see the end of this email for a list of signed statements from 
authors and people named in your paper that we will need before we can consider your 
paper further. Please scan and upload signed author statements and ICMJE conflict of 
interest forms for all authors with your revised submission. 




Comment 10 [General]: You will need to provide permission from the relevant publisher 
to include any material previously published that you wish to include in your paper. 
Response: We understand this but have not reproduced any material for which we need 
permission. 
 
Comment 11 [General]: Please provide: one preferred degree qualification per author and 
indicate any full professors; affiliation details (department, institute, city, state, country) 
for each author; full institutional correspondence address for corresponding author. 
Response: We have provided a preferred degree for each author as well as affiliation 
details. We have marked full professors in the manuscript with an asterisk (*). 
 
Comment 12 [General]: Please include, at the end of the main text, a "Contributors" 
section detailing the role of each author in the preparation of your paper. 
Response: Please see comment 3 above 
 
Comment 13 [General]: Please include, at the end of the main text, a "Conflicts of 
interest" statement summarising key conflicts from the ICMJE forms. The standard 
wording, if there are no conflicts is "We declare that we have no conflicts of interest." 
Response: Please see comment 4 above. 
 
Comment 14 [General]: For Reviews, Personal Views, Historical Reviews, and Grand 
Rounds please supply a 150-200 word unstructured summary of your manuscript. 
References should not be cited in the summary. 
Response: We have added some information to the abstract (as summary) so it is now 
160 words. 
Revised text: The global burden of disease caused by respiratory syncytial virus (RSV) is 
increasingly recognized, not only in infants, but also in older adults. Advances in 
knowledge of the structural biology of the RSV surface fusion (F) glycoprotein have 
revolutionized RSV vaccine development by providing a new target for preventive 
interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine 
candidates, including four approaches: (1)particle-based, (2)live-attenuated/chimeric, 
(3)subunit, (4)vector-based, as well as monoclonal antibodies (mAbs) in clinical trials, 
reflecting the urgency of reducing this global health problem and hence the prioritization 
of RSV vaccine development. Late phase RSV vaccine trial failures highlight gaps in 
knowledge regarding immunologic protection and provide lessons for future 
development. In this review we highlight promising new approaches to RSV vaccine 
design and provide a comprehensive overview of RSV vaccine candidates and mAbs 
currently in clinical development to prevent one of the most common and severe 
infectious diseases in young children and older adults worldwide.
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Comment 15 [General]: Images that have been published previously should be accompanied by a 
statement indicating permission to reproduce the image. If required, further assistance can be 
obtained from the editorial team. If you have borrowed published images from colleagues, you 
must obtain permission from the publisher of the paper, not just from the authors. If all the 
figures are your own and have not been published before then this requirement does not apply.  
Response: We do not have any relevant images or figures. 
 
Comment 16 [General]: Figure titles should be a maximum of 30 words. 
Response: We have kept our figure titles <30 words. 
 
Comment 17 [General]: References should be in the Vancouver style and numbered in the order 
in which they first appear in the manuscript. References in figures, panels, and tables should be 
numbered in sequence with the references in the text where that figure, panel, or table is cited. 
Please ensure tables and figures are cited correctly in the body text to prevent the need for 
renumbering of references should the table and figure citations subsequently move. 
Response: We have kept references in Vancouver style and adhered to other guidelines regarding 
references as mentioned above. 
 
Comment 18 [General]: For papers listed in references that are "in press" we need to see a galley 
proof and letter from the publisher stating that it is 'in press' as well as the full expected citation 
(ie, publication date/volume/issue etc). 
Response: We have included no references in press. 
 
Comment 19 [General]: Please ensure that references are not inserted as Footnotes. 
Response: We have no references as footnotes. 
 
Comment 20 [General]: For Reviews, Historical Reviews, and Grand Rounds, please supply a 
section entitled "Search strategy and selection criteria". This should state clearly the sources 
(databases, journals, or book reference lists, etc) of the material covered and the criteria used to 
include or exclude studies. Please state which search terms, languages and date ranges were 
used. 
Response: Please see comment 7 above. 
 
Comment 21 [General]: Please include the signatures of any people whose names were on a 
previous version of this manuscript as an author but have now been deleted, or reclassified as an 
acknowledgment. Ex-authors should declare that they have agreed to have their names deleted or 
reclassified. 
Response: There has been no change of authors since the last version of the manuscript. One 
author (Dr. José Melero) has passed away since the previous submission. Is it possible to add a 
posthumous note in the manuscript? 
 
Comment 22 [General]: If you have added to or changed the order of existing authors, we require 
signed statements from ALL authors that they are happy with these changes. 
Response: There is no change to author order since the previous manuscript. 
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Comment 23 [General]: Guidelines on electronic submission of text and figures are available at: 
http://ees.elsevier.com/thelancetid/. Please read these carefully; to ensure efficient prpreparation 
for publication, the text and figures should conform to these guidelines. 
Response: We have adhered to your guidelines. 
 
Comment 24 [General]:  All authors are required to provide a Conflict of Interest Statement and 
should complete a standard form, which is available 
at http://download.thelancet.com/flatcontentassets/authors/icmje-coi-form.pdf. This form can be 
uploaded with the manuscript at submission. The form has been modified by the ICMJE 
following consultation with authors and editors. Further information is available in a joint 
ICMJE statement published on July 1, 2010. For more information see Lancet 2009; 374: 1395-
96. 
In summary, the signed statements we require are:  
* Signed conflict of interest statements for ALL authors 
Response: We have made sure that all authors have submitted conflict of interest forms. 
 
Comment 25 [General]: All authors should complete and sign the author statement form and 
upload the signed copy. The form can be downloaded from the page 
(http://www.thelancet.com/lancet-infectious-diseases-information-for-authors/statements-
permissions-signatures#conflicts-of-interest) from the fourth line of "Authors and contributions". 
The corresponding author must countersign manually the forms at the bottom of the page and 
send us the scanned version; electronic signatures are not accepted. 
In summary, the signed statements we require are:  
* Authors' contributions - signed by yourself and your co-authors indicating that you have all 
seen and approved the paper 
Response: We have made sure that all authors have author statement forms, which have been 





Reviewer #1:  
 
Comment 1 [General]: The manuscript entitled "The Respiratory Syncytial Virus Vaccine 
Landscape" is an comprehensive review of vaccine and mABs candidates in clinical trials to 
prevent hRSV infection. They review from lessons of the failure of the first vaccines, explaining 
the different vaccines undergoing clinical trials that are reported according to PATH, the 
antigens use for vaccines against RSV and the target populations. The article describes the 
preventive strategies under clinical development addressing the problem caused by the RSV 
infection globally. It intends to provide updated information about the prophylactic and active 
immunization strategies currently under evaluation to prevent RSV infection. The manuscript 
includes bibliographic information, communications performed in the last RSV meeting in 2017 
and information made public through several websites, such as clinicaltrials.gov. It also 
discussed strategies that have failed to meet clinical endpoints with the aim 
of providing information that should be considered for the current strategies under evaluation 
and future candidates moving to clinical evaluation. The manuscript is well organized and meets 
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the aim to provide the complete landscape of RSV vaccines and antibodies under clinical 
evaluation. However, there are several corrections that the authors need to perform before the 
manuscript be accepted for publication. 
Response: Many thanks for thoroughly revising the manuscript. We have done our best to 
address all concerns mentioned. 
 
Major comments:  
 
Comment 2 [Reference]: Lack of references to support some statements throughout the text (For 
example, lines 108, 113, 153, 156, 280, 396, 430, 455, 463, 500, 520, 578, 600). 
 
Referring to: 108, Motivazumab, a higher affinity variant of palivizumab, was developed in early 
2000 but was withdrawn in 2010 
Response: We have added a reference for this statement. 
Revised text:  
Mazur NI, van Delden JJ, Bont LJ. Respiratory syncytial virus trials and beyond. Lancet Infect 
Dis. 2015 Dec;15(12):1363–5. 
 
Referring to: 113, Without evidence of superiority for protection from RSV-related 
hospitalization, evidence of slightly higher side effects, and no plan for dose reduction or cost-
saving, the product did not attain regulatory approval. 
Response: We have added a reference for this statement. 
Revised text:  
1. Carbonell-Estrany X, Simoes EAF, Dagan R, Hall CB, Harris B, Hultquist M, et al. 
Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A 
Noninferiority Trial. Pediatrics. 2010 Jan 1;125(1):e35–51. 
2. Feltes TF, Sondheimer HM, Tulloh RMR, Harris BS, Jensen KM, Losonsky GA, et al. A 
Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of 
Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically 
Significant Congenital Heart Disease. Pediatr Res. 2011 Aug;70(2):186–91. 
 
Referring to: 153, The results of the preceding phase II RSV F nanoparticle trial suggested the 
candidate vaccine might have modest efficacy. 
Response: We have added a reference for this statement. 
Revised text:  
Novavax. Positive Topline Data from Phase 2 Older Adult Trial and Path Forward for RSV F 




Referring to: 156, In the phase III trial, 11,586 subjects ≥60 years of age were enrolled in 60 US 
sites in a double-blind placebo-controlled trial (RESOLVE) over a single season starting 
November 2015 with 330 days follow-up. 
Response: We have added a reference for this statement. 
Revised text:  
 8 
ClinicalTrials.gov. A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults 
[Internet]. NIH: US National Library of Medicine. 2017 [cited 2018 Mar 26]. Available from: 
https://clinicaltrials.gov/ct2/show/study/NCT02608502?show_locs=Y 
 
Referring to: 280, A combined strategy that utilizes maternal vaccination to protect young infants 
followed by pediatric vaccination may be effective to prevent severe RSV infection in young 
children. 
Response: We have added a reference for this statement. 
Revised text:  
Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory 
syncytial virus disease and potential effect of different immunisation strategies: a modelling and 
cost-effectiveness analysis for England. Lancet Public Heal. Elsevier; 2017 Aug 1;2(8):e367–74. 
 
Referring to: 396, Assays of serum virus neutralization, RSV F-specific antibodies, palivizumab-
competing antibodies and F-specific IgA indicated some immunogenicity, but the results did not 
reach the threshold set for continuation to viral challenge and the studies were suspended in 2017 
(Openshaw and Chiu, personal communication). 
Response: Unfortunately there is no published material to support this statement but we feel it is 
valuable to include. We have received written consent from both authors for this personal 
communication to publish these results. 
 
Referring to: 430, The anticipated use for this pediatric vaccine is to start immunization at two 
months of age, and to use two to three doses alongside the normal pediatric vaccination schedule, 
instead of seasonally. This vaccine candidate is currently being evaluated in 12-23 month old 
RSV seropositive children. 
Response: We have added a reference for this statement. 
Revised text:  
Dieussaert I. GSK’s Pediatric RSV Vaccine Program. In: Presentation at Food and Drug 
Administration (FDA) 150th Meeting of the Vaccines and Related Biological Products Advisory 
Committee Meeting (VRBPAC). Silver Spring; 2017. 
 
Referring to: 455, Preliminary results from the phase I trial, VRC 317, are promising and will 
soon be published. 
Response: As this is also unpublished, we have softened the statement, as we cannot provide 
published sources to support it. However, we expect these results to be published based on their 
release at the RSV Vaccines meeting. 
Revised text: Preliminary results from the phase I trial, VRC 317, are promising and are 
expected to be published soon. 
 
Referring to: 463, Phase I results on safety and immunogenicity in the older adult population will 
soon be published from an investigator-initiated study. 
Response: There is no published citation to support this statement. Since the phase I study has 
been completed and the data presented in a poster at the RSV Vaccines for the World meeting in 
Malaga, we expect that the data will soon be published. We have changed the phrasing to say 
that we expect a publication of this data soon. We hope this is acceptable. 
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Revised text: Phase I results on safety and immunogenicity in the older adult population have 
been released and are expected to be published from this investigator-initiated study. 
 
Referring to: 500, Importantly, this candidate is the only vaccine candidate intended for 
administration to newborn infants. 
Response: We have added a reference for this statement. 
Revised text:  
Rey-Jurado E, Soto J, Gálvez N, Kalergis AM. A safe and efficient BCG vectored vaccine to 
prevent the disease caused by the human Respiratory Syncytial Virus. Hum Vaccin Immunother. 
Taylor & Francis; 2017 Sep 2;13(9):2092–7. 
 
Referring to: 520, Other emerging approaches not yet in clinical development include nucleic 
acid-based vaccines. 
Response: We have added a reference for this statement. 
Revised text:  
Smith TRF, Schultheis K, Broderick KE. Nucleic acid-based vaccines targeting respiratory 
syncytial virus: Delivering the goods. Hum Vaccin Immunother. 2017 Nov 2;13(11):2626–9. 
 
Referring to: 578, Given that the most severe RSV infection occurs in LMICs, information 
regarding LMIC target countries and potential pricing for vaccine candidates will be essential to 
facilitate access to vaccines worldwide, especially in areas where the mortality burden is highest. 
Response: We have added a reference for this statement. 
Revised text:  
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi S a, Singleton RJ, et al. Global burden of 
acute lower respiratory infections due to respiratory syncytial virus in young children: a 
systematic review and meta-analysis. Lancet. Elsevier Ltd; 2010 May 1;375(9725):1545–55. 
 
Referring to: 600,Viral interference, in which RSV inhibits infection by other viruses, is 
becoming an increasingly important concept to understand in the context of an approved RSV 
vaccine. RSV vaccination may conceivably result in an increased or decreased prevalence of 
other respiratory viruses. 
Response: This sentence is used to introduce the following sentences, which mention evidence of 
viral interference after influenza vaccination, after RSV prevention and cross-sectionally in the 
absence of RSV during the RSV season. We have cited 5 peer-reviewed articles to support that 
viral interference exists and our interpretation is that this is an important concept in the context 
of RSV vaccination and could conceivable result in increased prevalence of other viruses. 
 
Comment 3 [Reference]: References should be original articles or review but not oral 
communications (Lines 455 and 396) 
Referring to: 
396, The preliminary results of immunogenicity testing have been reported. The immunogenicity 
of this vaccine was evaluated after delivery as a nasal spray to healthy adult volunteers. Two 
intranasal doses of SynGEM were administered 28 days apart at low or high dose in 24 subjects 
per group (6 subjects in each group receiving placebo, double blinded). Assays of serum RSV F-
specific antibodies, palivizumab-competing antibodies and F-specific IgA indicated some 
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immunogenicity, but the results did not reach the threshold set for continuation to viral challenge 
and the studies were suspended in 2017 (Openshaw and Chiu, personal communication). 
 
455, Preliminary results from the phase I trial, VRC 317, are promising and will soon be 
published (Graham, personal communication). 
Response: Unfortunately there is no published material to support this statement but we feel it is 
valuable to include. We have received written consent from both authors for this personal 
communication to publish these results. 
 
Comment 4 [Other approaches]: The section "Other approaches not in clinical development" is 
too short and is not taking into account all the vaccine and Ab candidates that are reported under 
preclinical development in the PATH report  (Line 520). 
Response: The aim of the manuscript is to give a detailed overview of RSV vaccine candidates in 
clinical development. We have decided to mention other promising approaches to RSV vaccine 
development, however this is not an exhaustive coverage of all candidates in preclinical 
development as this is outside of the scope of the manuscript. We have mentioned only 
approaches that are not mentioned earlier in the rest of the manuscript to give a sense of other 
new approaches to developing an RSV vaccine: namely nucleic-acid based vaccines and 
biosimilars. The only approach we have not added that is not mentioned elsewhere is whole-
inactivated vaccines but this is not a “new approach” which is why we had not mentioned it. 
However, we have now added whole-inactivated vaccines to this section so that all vaccine 
approaches in clinical and pre-clinical development are covered. 
Revised text: Finally, another vaccine approach in preclinical development is a whole-inactivated 
vaccine to be delivered intranasally via a nanoemulsion technology for which development has 
been supported by the Bill & Melinda Gates Foundation(99). 
 
Comment 5 [Table 1]: Some data are cited on the table 1 but not throughout the text (For 
example Line 500). 
Referring to: Importantly, this candidate is the only vaccine candidate intended for 
administration to newborn infants.  
Response: We have added the citations from the table into the text for the rBCG-N-hRSV 
vaccine candidate. However, table 1 provides a comprehensive overview of all vaccine 
candidates while the text highlights key elements. The length of the review does not allow us to 
mention every element of the table in the text. Please let us know if there are specific elements 
you feel are underrepresented. 
Revised text: 
1. Bueno SM, Gonzalez PA, Cautivo KM, Mora JE, Leiva ED, Tobar HE, et al. Protective T cell 
immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc 
Natl Acad Sci. 2008 Dec 30;105(52):20822–7.  
2. Cautivo KM, Bueno SM, Cortes CM, Wozniak A, Riedel CA, Kalergis AM. Efficient lung 
recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus 
Calmette-Guérin promotes virus clearance and protects from infection. J Immunol. 2010 Dec 
15;185(12):7633–45. 
3. Céspedes PF, Rey-Jurado E, Espinoza JA, Rivera CA, Canedo-Marroquín G, Bueno SM, et al. 
A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity 
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against the human respiratory syncytial virus infection and prevents lung pathology in mice. 
Vaccine. 2017 Feb 1;35(5):757–66.   
 
Comment 6 [Table 1]: The status for clinical evaluation is outdated for some of the vaccines 
described. For example the following trial was omitted NCT03213405 (from 
www.clinicaltrials.gov) for a vaccine described in these references that should be added: 
Vaccine. 2017 Feb 1;35(5):757-766. doi: 10.1016/j.vaccine.2016.12.048. Proc Natl Acad Sci U S 
A. 2008 Dec 30;105(52):20822-7. doi: 10.1073/pnas.0806244105. 
Response: The trial you mention was already in the table and the correct phase has been listed 
for this vaccine candidate (phase I). Both publications mentioned have also already been cited 
both in the text and in the table (please refer to comment 4 above, we have added these citations 
to the text as they were already in the table. The phases we list for all trials are up to date 
according to the PATH vaccine snapshot. 
 
Comment 7 [General]: Authors failed to cite some recent papers on RSV vaccines and should 
include: Vaccine. 2017 Jan 11;35(3):489-495. doi: 10.1016/j.vaccine.2016.08.086. Vaccine. 
2017 Jan 11;35(3):496-502. doi: 10.1016/j.vaccine.2016.09.026. Vaccine. 2016 May 
27;34(25):2847-54. doi: 10.1016/j.vaccine.2016.04.002. 
Controlled human infection with RSV: The opportunities of experimental challenge. 
Response: Many thanks for these suggestions. We have added a sentence in immunologic 
endpoints regarding the opportunities and challenges with controlled human infection as well as 
the reference you mention: 
So far no vaccine candidates have been tested with experimental human infection model, but the 
model provides a unique opportunity to test vaccine candidates in the natural host despite 
practical and ethical challenges(81). 
We have also added the first-in-human trial for MEDI7510: 
The vaccine candidate showed safety and immunogenicity with elevated B and T cell responses 
in the vaccine group compared to the placebo group in phase I clinical trials(43) after safety and 
improved immunogenicity with an adjuvant was demonstrated in a first-in-human trial(44). 
The last reference you mention is a review of  novel antibodies for the prevention and treatment 
of RSV. We have used this as a resource to cross-reference our own manuscript but have not 
cited this reference in the text as no information used primarily came from this manuscript. 
 
Comment 8 [Introduction, Methods, RSV Vaccine History]: Some parts of the manuscript 
required edition for writing, gramma and spelling. For instance, from pages 5 to 8, most of the 
sentences are too long and some of them are not clear: line 12 "young infants passive 
immunization". The sentence is not clear. Should be "young infants through passive 
immunization"?. Lines 34-36, the sentence is too long. Lines 50-54. Again, the sentence is too 
long, authors should either add colons or break the sentence in two. 
Response: Thank you for bringing this to our attention. Line 12 was a typo and has been changed 
to read “young infants through passive immunization” as you suggest. We agree that the 
sentence for lines 34-36 was too long and not clear and have shortened and clarified it. We have 
also condensed the sentence in lines 50-54 and hope you will now find it reads more clearly. 
Revised text: 
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Lines 34-36: Another challenge to RSV vaccine design is the lack of consensus regarding 
vaccine trial clinical endpoints though attempts have been made to define these for RSV 
prevention trials(14–16). 
Referring to: Second, the discovery of the structure and stabilization of the prefusion (pre-F) 
conformation of the RSV F protein has advanced the field by showing that pre-F specific 
antibodies may be more potent in protecting against RSV LRTI than antibodies that also bind the 
postfusion (post-F) conformation and by thus providing a new target for vaccines and 
mAbs(21,22). 
Lines 50-54: Second, the discovery and stabilization of the prefusion (pre-F) conformation of the 
RSV F protein provided a new target for vaccines and mAbs(21,22) as pre-F specific antibodies 
may be more potent than postfusion (post-F) antibodies in protecting against RSV LRTI. 
 
Comment 9 [RSV Vaccine History]: Line 107. "Motivazumab" should be replaced for for 
"Motavizumab". 
Response: We have changed this as suggested, thank you for pointing out this typo. 
 
Comment 10 [RSV Vaccine History]: Line 125. For better fluidity and coherence, please add a 
brief comment about the clinical development of these live attenuated vaccines and a sentence 
indicating that additional information will be discussed in a following chapter. 
Referring to: After reverse genetics techniques became available in the 1990s, it became possible 
to design vaccineswith the appropriate level of attenuation, but with increased 
immunogenicity(32). 
Response: To prevent the manuscript becoming too lengthy we have left the paper as is. Please 
let us know if additions are required. 
 
Comment 11 [RSV Vaccine History]: Lines 9-8 "The mortality attributable to RSV in adults > 
65 year of age is estimated to be 7.2 per 100,000 person year". Authors should clarify whether 
this is a global estimate or refers to data from the US. 
Response: We agree this needs to be clarified and have added that this is an estimate from the 
US. 
Revised text: The mortality attributable to RSV in adults ≥65 years of age is estimated to be 7.2 
per 100,000 person years in the United States(3). 
 
Comment 12 [Introduction]: Lines 18-24. The information provided here should be moved to 
"RSV vaccine history", line 96, to avoid redundancy through the text.  
Referring to: ERD occurred in RSV-naïve infants who experienced infection with community-
acquired wild-type RSV following receipt of FI-RSV. Decades of research have revealed that in 
these FI-RSV primed infants, natural RSV infection triggered a strong but non-neutralizing 
antibody response(5), followed by a T helper 2 (Th2) skewed immunologic response(6). The 
failure to mount a protective cytotoxic T lymphocyte (CTL) response was coupled with excess 
lung eosinophilia and neutrophilia, monocytic infiltration, and immune complex deposition in 
the lungs(7). 
Response: We agree and have moved this section to RSV vaccine history as suggested. 
 
Comment 13 [Introduction]: Lines 385-387. These sentences are not clear, it seems that some 
information is missing. 
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Referring to: The platform in which an antigen is presented by a bacterial particle has shown 
both local and systemic antibody responses for the influenza candidate in clinical trials using the 
same platform(79) 
Response: We agree that this sentence was not clearly worded. We hope you will find the 
revision acceptable. 
Revised text: The influenza vaccine candidate in clinical trials which uses the same vaccine 
platform, has shown both local and systemic antibody responses(85). 
 
Comment 14 [References]: Some of the references are not properly cited and should be 
amended:  
Several the links for the websites cited in the manuscript are not working (Ref 11, 74). These 




Referring to: 11 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/11/WC500216809.pdf 
Response: The link to this website works, could you please clarify your comment? We have cited 
everything according to Vancouver citation style as a website. 
 
Referring to: 17 
http://www.nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=16/284 
Response: We believe you are referring to citation 74 instead of 17. In this case, the link works 
as well so we have undertaken no action. The link goes to the website at which one can 
download the NIBSC Antiserum to RSV WHO 1
st
 international standard instructions for use. 
 
Comment 15 [General]: Authors should include a brief discussion about the advantages and 
disadvantages of the enhanced disease models currently available as a pre-clinical test required 
for candidates to advance into clinical trials. 
Response: We agree that this would be a valuable addition to the manuscript and have added a 
brief discussion as suggested to the section on immunologic endpoints. 
Revised text: 
Animal models are important for preclinical development of vaccine candidates and assessing 
the possibility of enhanced disease. Alveolitis in the cotton rat and priming of a Th2 response in 
mice are considered markers to assess ERD; there is no consensus on the ability to reproduce 
ERD in calves(80). So far no vaccine candidates have been tested with experimental human 
infection model, but the model provides a unique opportunity to test vaccine candidates in the 
natural host despite practical and ethical challenges(81). 
 
Reviewer #2:  
 
Comment 1 [General]: This review article provides a good overview of the current state of the 
RSV vaccine field including an comprehensive overview of the vaccine candidates currently 
undergoing clinical trials. Overall, the review is well written and fairly comprehensive.  It could 
benefit from an expanded discussion regarding what is known about the deficits in immunity 
following a natural RSV infection as this is critical for trying to develop an efficacious vaccine 
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as well as more discussion regarding the potential importance of developing vaccine approaches 
that will elicit both cell mediated immunity in addition to humoral immunity.  
Response: We thank the reviewer for the comprehensive review of the manuscript. The aim of 
the manuscript is to focus on vaccine candidates in clinical development with a short overview of 
vaccine development history, important vaccine failures, target populations and immunologic 
endpoints. Unfortunately discussing cell-mediated immunity and deficits in immunity in detail is 
beyond the scope of this manuscript, as this would require a separate review. We hope the 
reviewer will find this acceptable. We realize this is a limitation of the manuscript and have 
mentioned this in the section on immunologic endpoints. 
Revised text: Although we discuss several potential immunological correlates of protection for 




Comment 2 [General]: The discussion of ERD caused by the FI-RSV vaccine should include the 
study by Knudson et al PLoS Pathogens 2015 11(3):e1004757 as it demonstrates the critical role 
of CD4 T cells in mediating ERD as well as calling into question the implication that eosinophils 
contributed to the pathology. 
Response: We have added this reference in the section on ERD as suggested. 
Revised text: Other aspects of the immune response implicated in ERD include distinct subsets 
of CD4 cells(24) and memory CD8 T cells(25). 
 
Comment 3 [General]: The section on the failure to license Motivazumab on page 7 does not 
really add to the review and could easily be cut to allow for additional focus on other areas. 
Response: Thank you for this comment. Although we understand your objection, we believe the 
failure of motavizumab to gain FDA approval after 3 phase III trials is an important part of RSV 
vaccine history given the large investment, demonstrated efficacy and late-stage failure and have 
therefore decided to leave this part in. 
 
Comment 4 [Immunologic endpoints]: The immunologic endpoints section should include an 
enhanced discussion of the potential importance of the induction of cell mediated immunity in 
combination with humoral immunity and how one may measure cell mediated immunity 
endpoints.  
Response: Please refer to response to comment 1 above. 
 
Comment 5 [General]: The authors should consider recent papers examining the role of T cell 
responses to RSV including Schmidt et al PLoS Pathogens 2018 14(1):e1006810, Scheible et al 
JCI Insight 2018 3(4) pit: 96724 [Epub ahead of print], and Mariani et al J Infect Dis 2017 
216(8): 1027-1037. 
 
Referring to: Schmidt et al PLoS Pathogens 2018 14(1):e1006810 
Response: Thank you for this excellent suggestion, we have included this reference in the section 
on immunologic mechanisms of ERD. 
Revised text: Other aspects of the immune response implicated in ERD include distinct subsets 
of CD4 cells(24) and memory CD8 T cells(25). 
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Referring to: Scheible et al JCI Insight 2018 3(4) pit: 96724 [Epub ahead of print] 
Response: Although this reference is an important contribution to the body of knowledge 
regarding T cell development and abnormal health outcomes for infants, we feel that it does not 
fit the scope of the manuscript and have decided not to include it. 
 
Referring to: Mariani et al J Infect Dis 2017 216(8): 1027-1037. 
Response: Please see response above. 
 
Reviewer #3:  
 
General Comments to Authors: 
 
Comment 1 [General]: This manuscript represents a review of an extremely important topic for 
the health of the worlds pediatric and adult populations.   The topic of advances in the prevention 
of respiratory syncytial virus is timely as well.  Furthermore, the authors represent an august 
group with International experience and reputation on this particular subject.   
Response: We are happy the reviewers agree that the manuscript is timely and written by a wide 
range of experts on the subject. 
 
Comment 2 [General]: The manuscript could be improved in two important areas: first, the 
manuscript needs to have more attention devoted to RSV in adults, especially because this is the 
likely first population group for which vaccines will be developed.   
Response: Thank you for this suggestion. Following the comments below we tried to devote 
more attention to RSV in adults as the reviewer suggests. 
 
Comment 3 [General]: Second, the manuscript has a potentially very valuable section devoted to 
recent lessons Learned from recent clinical trial failures.  This section needs to be updated and 
expanded using all available publicly accessible evidence.   
Response: Although, we understand the reviewers comments, we have tried to be complete. We 
welcome any missing information as we have indeed attempted to use all available information. 
 
Comment 4 [General]: Third, the manuscript needs more attention devoted to an integrated 
discussion of monoclonal antibodies.  More detailed line - specific comments are provided 
below. 
Response: We have followed the reviewer’s suggestions below to devote more attention to the 
discussion of monoclonal antibodies. 
 
Detailed Comments to Authors: 
 
Comment 5 [Introduction]: Lines 14-15 This paragraph starts out lumping RSV vaccines and 
monoclonal antibodies together in the title sentence (which is a good idea). However, the 
discussion which follows is solely focused on vaccines and the problems encountered in their 
development.  It is important to include a statement that monoclonal antibodies have avoided 
these issues. 
Referring to: Development of effective RSV vaccines and monoclonal antibodies (mAbs) 
presents both opportunities and challenges. 
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Response: We agree that the introduction does not give a balanced introduction of both vaccine 
candidates and monoclonal antibodies and have revised the introduction to now include both. 
Revised text:  
We have added the following two sentences: 
Despite these obstacles, there are several opportunities for RSV vaccine and monoclonal 
antibody development. 
Monoclonal antibodies circumvent the problem of transient immunity to RSV and an immature 
immune response to vaccination in young infants at risk of severe disease. 
 
Comment 6 [Introduction]: Lines 20-24 I believe that the authors may be inadvertently 
mischaracterizing the data from all of these referenced papers. The authors must make a clear 
delineation as to what they are talking about. Are they talking about the vaccine failing to do 
these things, or are they talking about the natural RSV infection after the vaccine failing to do 
these things.? The way it is written, the authors are talking about the natural infection (following 
the vaccine) which failed to do these things.  This is a very important part of this review, and it 
needs to be explained correctly and well.  
Referring to: Decades of research have revealed that in these FI-RSV primed infants, natural 
RSV infection triggered a strong but non-neutralizing antibody response(5), followed by a T 
helper 2 (Th2) skewed immunologic response(6). The failure to mount a protective cytotoxic T 
lymphocyte (CTL) response was coupled with excess lung eosinophilia and neutrophilia, 
monocytic infiltration, and immune complex deposition in the lungs(7). 
Response: The intention of this statement is to talk about the response to natural RSV infection 
following priming with a FI-RSV However, we agree that it is unclear as written that the priming 
with FI-RSV results in low avidity antibodies and skews the immune system towards a Th2 
response upon natural RSV infection. The 2010 Nature Medicine paper by Polack et al describes 
FI-RSV induction of low affinity antibodies which led to severe disease upon exposure to RSV. 
The 2006 Nature Medicine paper by Moghaddam et al boosts Th2 responses in mice. We hope 
the reviewer feels that the revision is clearer. 
Revised text: ERD occurred in RSV-naïve infants who experienced infection with community-
acquired wild-type RSV following receipt of FI-RSV. Decades of research have revealed that 
priming with FI-RSV triggered a strong but non-neutralizing antibody response(22), followed by 
a T helper 2 (Th2) skewed immunologic response(23) which may lead to ERD upon natural RSV 
infection 
 
Comment 7 [Introduction]: Lines 30-33 The failure of these referenced trials includes 
inadequacies in the study design, Logistics, and implementation. It is not necessarily the fault of 
gap in knowledge but rather the fault in implementation that drove the studies to fail.  This 
statement needs to be softened so as to make it clear that in certain regards a Failure may just be 
logistic.  This reviewer has personally evaluated the data sets for two of these three reference 
trials, and this evaluation is the basis for this reviewer's comment.  Additionally, putting all of 
the blame on gaps in knowledge tends to inappropriately paralyze the vaccine and monoclonal 
antibody development pathways, which need to be open and active. 
Referring to: Recently, three phase IIb/III trials (two vaccine trials in older adults(11,12) and one 
mAb trial in infants(13)) failed to meet clinical endpoints. The failure of these vaccine and mAb 
candidates demonstrates the continued gaps in knowledge regarding immunologic mechanisms 
of protection in the different target populations.   
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Response:  We have rephrased this sentence to soften it and also acknowledge the importance of 
inadequacies of trial design. 
Revised text: In addition to possible inadequacies in trial design and implementation, the failure 
of these vaccine and mAb candidates demonstrates the continued gaps in knowledge regarding 
immunologic mechanisms of protection in the different target populations 
 
Comment 8 [Introduction]: Lines 34-36 It is not clear what is meant buy endpoints of vaccine 
treatment trials.  I think that the authors should limit the discussion to RSV prevention strategies, 
rather than therapeutic vaccines which are highly controversial. 
Referring to: Another challenge to RSV vaccine design is the lack of consensus regarding 
clinical endpoints of vaccine trials though attempts have been made to define these for both 
prevention(14–16) and treatment trials(17). 
Response: We agree with the reviewer and have revised the text so that only prevention is 
mentioned and not treatment trials. 
Revised text: Another challenge to RSV vaccine design is the lack of consensus regarding 
vaccine trial clinical endpoints though attempts have been made to define these for RSV 
prevention trials(11–13). 
 
Comment 9 [Introduction]: Lines 43 This is an ideal place to start talking about the advantages of 
passive antibody prophylaxis with monoclonal antibodies.  In general, the discussion has been 
far too RSV vaccine focused and has neglected monoclonal antibodies in the discussion.  The 
authors need to add a brief section here on the advantages of monoclonal antibodies which 
overcome this problem of in infants.   
Referring to: An ideal RSV vaccine candidate should prevent severe disease in at risk 
populations. 
Response: We agree that this is a good place to add a section on the advantages of monoclonal 
antibodies and have added this as per suggestion.  
Revised text: Monoclonal antibodies circumvent the problem transient immunity to RSV and an 
immature immune response to vaccination in young infants at risk of severe disease. 
 
Comment 10 [Introduction]: Lines 45 The authors need a reference to this statement.  The 
prospect of herd immunity to RSV provided by a putative RSV vaccine has been modeled.  I 
believe the paper is found in Proceedings of the National Academy of Sciences, Senior author: 
Galvani. 
Referring to: Certain vaccines might also lessen person-to-person transmission and thereby 
provide secondary benefits in those who cannot benefit directly from vaccination. 
Response: Thank you for this excellent suggestion, we have added the reference you suggest. 
Revised text: 
Yamin D, Jones FK, DeVincenzo JP, Gertler S, Kobiler O, Townsend JP, et al. Vaccination 
strategies against respiratory syncytial virus. Proc Natl Acad Sci. 2016 Nov 15;113(46):13239–
44. 
 
Comment 11 [Introduction]: Lines 64 This introduction continues to be too focused on vaccine to 
the exclusion of a discussion of monoclonal antibodies.  Also, the authors focused too much on 
pediatrics to the relative amount of the discussion devoted to adult issues 
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In the context of RSV as an increasingly recognized global health problem, these rapid changes 
and expansion show the prioritization of RSV vaccine development. 
Response: We agree and have rephrased vaccine to vaccine and mAb for the “opportunities” 
paragraph at the end of the introduction. Although we only wrote vaccine, these opportunities are 
equally relevant for mAbs in clinical development. For the rest, we do not believe the 
introduction to be more focused on pediatric populations than adults as the focus of the 
introduction is to lay out the challenges and opportunities to RSV vaccine and mAb 
development. Please let us know if you find this acceptable as now written. 
Revised text: In the context of RSV as an increasingly recognized global health problem, these 
rapid changes and expansion show the prioritization of RSV vaccine and mAb development. 
 
Comment 12 [RSV Vaccine history]: Lines 104 The authors need to include the polyclonal RSV 
immune globulin manufactured by ADMA Biologics (RI-002) (ADMA Biologics, Ramsey, NJ, 
USA). This is-FDA approved as an immune globulin, and has been manufactured to mimic 
Respigam, but it did not receive the "FDA indication" of RSV preventing because the trials were 
not performed for that purpose (due to immense const).  However, it is approved for use as a 
replacement for Primary Immune Deficiencies.   
Referring to: Since its initial approval in 1998, palivizumab remains the only licensed preventive 
intervention against RSV(27). 
Response: Although we understand that RI-002 is an approved polyclonal antibody with high 
RSV-neutralizing antibodies, we believe that RI-002 falls outside the scope of this manuscript as 
it was not developed as a strategy for RSV prevention specifically (but immunoglobulin 
supplementation in PIDD patients) and is not included in the PATH vaccine snapshot. The Phase 
III trial showed efficacy against serious bacterial infections but not against RSV. As a review of 
novel antibodies (Mejias et al, Vaccine 2017) mentioned “The role of RI-002 in preventing RSV 
infection in this population has not been reported.” The aim of this manuscript is to focus on 
prevention strategies in clinical development on the basis of the PATH snapshot. We have 
therefore decided not to include it in the manuscript. We hope the editor finds this acceptable. 
 
Comment 13 [RSV Vaccine history]: Lines 106 The authors need to mention the efficacy of 
palivizumab in the various populations evaluated (including mentioning the approximately 80% 
reduction in RSV-hospitalizations in infants with milder degrees' prematurity and without 
chronic lung disease.  
Referring to: Palivizumab has an excellent safety profile and is indicated for the prevention of 
severe RSV ALRI in children born prematurely, with congenital heart disease, or with chronic 
lung disease(28).  
Response: We agree that adding some information about the efficacy of palivizumab IMPACT-
RSV trial is informative and have mentioned the efficacy from this trial in premature children 
without BPD. 
Revised text: Since its initial approval in 1998, palivizumab remains the only licensed preventive 
intervention against RSV after demonstrating a reduction of 39% to almost 80% reduction of 
RSV hospitalization in preterm infants < 35 weeks gestational age with and without chronic lung 
disease respectively(29). 
 
Comment 14 [RSV Vaccine history]: Lines 111 The authors need to replace the word evidence 
with the words "sufficient evidence".   
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Referring to: Without evidence of superiority for protection from RSV-related hospitalization, 
evidence of slightly higher side effects, and no plan for dose reduction or cost-saving, the 
product did not attain regulatory approval. 
Response: We have made the revision as suggested. 
Revised text: Without sufficient evidence of superiority for protection from RSV-related 
hospitalization, evidence of slightly higher side effects, and no plan for dose reduction or cost-
saving, the product did not attain regulatory approval. 
 
Comment 15 [RSV Vaccine history]: Lines 118 I think it is important to mention that the other 
vaccine strategies were not allowed to be tried in infants (rather than they were tried and found to 
be unsafe) needs to be expanded. It was the regulators who haven't allowed this. Not necessarily 
the investigators.  If I am mistaken on this point, please help me and the reader understand.   
Referring to: With respect to vaccines for active immunization, many approaches targeted for 
RSV naïve children were evaluated pre-clinically over the years. Only live-attenuated vaccine 
candidates were considered safe for clinical evaluation in these children(31). 
Response: We have decided to remove this sentence. 
 
Comment 16 [RSV Vaccine history]: Lines 139 So what is the lesson learned from this? The 
reasons for failure?  Is there a new set of information from the Regeneron website?  What about 
clin trials.gov? What about the half-life of the antibody with respect to the target dosing interval? 
 Was it a failure of efficacy or a failure as safety?  All these questions need to be addressed. We 
need to be able to learn a lesson, rather than have a bunch of questions still hanging. 
Referring to: A phase III double-blind, placebo-controlled trial (NURSERY) evaluating 
REGN2222, a mAb against antigenic s V on the RSV pre-F protein, a major target for high-
potency mAbs(37) was conducted. 
Response: We agree upon the importance of learning a lesson from these large late-phase 
vaccine trial failures. Unfortunately, the lack of information available in the public domain (and 
lack of any peer-reviewed publication) make it very difficult to distil any lessons learned. This is 
exactly why we emphasize the importance of publishing these results and analyzing them in 
order to benefit future vaccine trials. Nevertheless, we have revisited clinicaltrials.gov, the 
Regeneron website, and any other published information to determine if we have missed any 
information. To address the question on whether it was a failure of efficacy or safety, we 
mentioned in the manuscript that the NURSERY trial did not meet its primary outcome to 
prevent medically-attended RSV infections which indicates that it was a failure of efficacy, not 
safety. The expected half-life of the antibody was not published. Only one or two doses were 
administered depending on the treatment arm. When two doses were administered, these were 
administered 8 weeks apart. It may be that this is not sufficient given the average half-life of 
antibodies to be was described in the poster as 32.0+/-8.79 and 34.4+/-11.9 days following IM 
administration of 3 mg/kg and 10 mg/kg doses, indicating the half life is longer than that of 
palivizumab. Unfortunately no new study results have been posted on the Regeneron website nor 
on clinicaltrials.gov. The only information in the public domain is a poster presentation from ID 
Week in 2015 on the phase 1 trial results 
(http://files.shareholder.com/downloads/REGN/0x0x853993/048D5B21-4FAD-4254-8299-
6547853FCAC6/REGN2222_IDWeek_2015_poster_HIGH_RES.PDF). We have also written to 
Regeneron to inquire whether there were further analyses of this late-stage failure performed and 
whether there is a plan for publication of these results. Unfortunately, given the lack of 
 20 
information we have only been able to speculate regarding the dosing interval and otherwise give 
the lack of information have called upon the company to analyze and publish phase III results. 
Revised text: A proposed explanation for the failure of this trial may be inadequate dosing 
schedule in regard to the antibody half-life. Ultimately, the basis for failing to meet the primary 
clinical endpoint is not known, as analyses of this late-stage failure have not yet been made 
public. 
 
Comment 17 [Lesson learned]: Lines 142 The authors need to add that these infants had to have 
been rejected from receiving palivizumab. (Full list of inclusion and exclusion criteria can be 
obtained at the Clintrials.gov website. 
Referring to: REGN2222 was administered once or twice during the respiratory season in 1,149 
healthy preterm infants < 6 months of age with a gestational age ≤35 weeks and did not meet its 
primary endpoint to prevent medically-attended RSV infections through day 150 of life. 
Response: We agree that this is important information and have added this to the manuscript. 
Revised text: REGN2222 was administered once or twice during the respiratory season in 1,149 
healthy preterm infants < 6 months of age with a gestational age ≤35 weeks who were not 
eligible to receive palivizumab prophylaxis 
 
Comment 18 [Lesson learned]: Lines 149. 2. The discussion of the second candidate is 
inadequate.  Additionally, the manufacturer/ sponsor (Novavax) (and the product name itself), 
needs to be identified, so as to be parallel to the discussion of the first candidate, (Regeneron).   
Referring to: The second candidate that failed to meet the predefined study endpoint in phase III 
clinical trials was the RSV F nanoparticle vaccine candidate for older adults, a candidate based 
on aggregates of full-length post-F. 
Response: Throughout the entire manuscript text we have not mentioned the names of 
pharmaceutical companies. The section on REGN2222 does not refer to Regeneron specifically 
even though the name of the mAb includes “REGN.” The only section of the manuscript where 
pharmaceutical names are mentioned is Table 1 under “Company/sponsor.” Furthermore, we 
have addressed comments 18-20 and hope that this has led to a more adequate discussion of this 
vaccine candidate. 
 
Comment 19 [Lesson learned]: Lines 158 The authors might consider a brief discussion of the 
appropriateness or inappropriateness of the controversial assay "palivizumab competing 
antibody". 
Referring to: Although the vaccine showed promising results in phase II and comparable 
immunogenicity measures in the two phases as determined by neutralizing and palivizumab-
competing antibody induction, the vaccine candidate failed to show efficacy against RSV 
moderate–severe lower respiratory tract disease (ms-LRTD) in phase III results(12). 
Response: We agree that this is important to understand the Novavax phase III failure and have 
added a sentence on PCA. 
Revised text: For example, PCA titers may not correspond to effective immunity as non-
neutralizing antibodies also bind the palivizumab binding site and can interfere with the binding 
of neutralizing antibodies(48). 
 
Comment 20 [Lesson learned]: In this reviewer's recollection, the neutralizing antibodies were 
not encouraging, But the PCA antibodies (Whatever that means) we're astoundingly high.   
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Referring to: Although the vaccine showed promising results in phase II and comparable 
immunogenicity measures in the two phases as determined by neutralizing and palivizumab-
competing antibody induction, the vaccine candidate failed to show efficacy against RSV 
moderate–severe lower respiratory tract disease (ms-LRTD) in phase III results(12). 
Response: We agree that in the public domain there is no clear data on increase of MN in the 
vaccination group compared to placebo (see for example: 
http://novavax.com/download/files/presentation/Novavax_RSV_Analyst_Day_7-24-
17_PDF2.pdf). Reported immunogenicity measures include anti-F IgG as well as PCA. We have 
clarified this in the text. 
Revised text: Another proposed explanation for failure of this vaccine candidate is that the 
quantity of the immune response to vaccination may not represent effective immunity. For 
example, PCA titers may not correspond to effective immunity as non-neutralizing antibodies 
also bind the palivizumab binding site and can interfere with the binding of neutralizing 
antibodies(48).  
 
Comment 21 [Lesson learned]: Lines 170-173 This was the company's stated reason.  However, 
it appears that the lack of a sufficient number of endpoints (RSV-MS- LR TD) was not the sole 
reason for the vaccine failure.  Because the vaccine affect size was also shown to be too low. 
 This needs to be brought out.  Also, it needs to be pointed out and appropriately referenced that 
low micro neutralization responses may have been achieved (If this information is attainable in 
published form).   
Response: Unfortunately, as stated earlier the MN titers for phase II and phase III are nowhere to 
be found in the public domain. Only the phase I results for the older vaccine candidate have been 
published (PMC5389002) which describes a 1.3-1.7 fold rise in neutralizing antibody titers in 
response to vaccination (see figure from manuscript included below). 
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The increase in RSV microneutralizion response in vaccines compared to placebo is not 
available in the public domain for the phase III trial so it is difficult to draw a conclusion, but in 
the phase I trial there was only a modest (1.3-1.7 fold) increase in neutralizing antibody titers in 
response to vaccination(49). 
Comment 22 [Lesson learned]: Lines 177 What was its primary objective?  Phase 2 clinical trials 
are not usually having a primary objective of vaccine efficacy. Rather they usually have a 
primary objective of immunogenicity. What was the immunogenicity? The statement that the 
authors make that "93% of VAX recipients in these had an anti-F antibody seroresponse" is 
inadequate for the reader to understand what that quantitative level of seroresponse was. 
Referring to: Development of the MEDI-7510 vaccine candidate, a subunit vaccine candidate for 
older adults, was discontinued after a phase IIb trial in North America, Europe, South Africa, and 
Chile in 1900 adults ≥60 years after the study failed to meet its primary objective. 
Response: The primary outcome specified on clinicaltrials.gov (NCT02508194) was the 
percentage of participant who had a first episode of acute RSV-associated respiratory illness 
(ARA-RI) during the RSV season in season 1 for day 14 through the end of the surveillance 
period (approximately 7 months). Immunogenicity measures (GM fold change in Anti-F IgG, 
RSV microneutralization post dose geometric mean fold change, PCA post-dose GMC) were 
only included as secondary outcomes. We have clarified that this was the specified primary 
outcome of the phase IIb trial. Furthermore, we agree that the immunogenicity measures were 
not reported in enough detail and have now added this to the manuscript. 
Revised text: 
Development of the MEDI-7510 vaccine candidate, a subunit vaccine candidate for older adults, 
was discontinued after a phase IIb trial in North America, Europe, South Africa, and Chile in 
1900 adults ≥60 years after the study failed to meet its primary objective, efficacy against RSV-
associated respiratory illness between 14 days post-vaccination throughout the end of the 
surveillance period, approximately 7 months. 
No efficacy was found in secondary subset analyses. On day 29, 93% of vaccinees had an anti-F 
IgG antibody seroresponse and there was a geometric mean fold rise in anti-F IgG titer of 4.6 at 
the end of the RSV season in vaccine recipients compared to the placebo group(50).  
 
Comment 23 [Lesson learned]: Lines 187 The authors need to add information regarding the 
neutralizing antibody concentrations that were induced by the vaccine.  This allows the reader to 
understand things about epitope specificity.   
Referring to: One proposed explanation for the negative results may be that the choice of a post-
F antigen induced antibodies without appropriate epitope specificity(40). 
Response: We agree that this would be helpful to interpret whether epitope specificity played an 
important role in phase IIb failure. However, unfortunately the only data published show MN 
response at baseline and on day 29 after dosing in subjects who met the primary end point or 
were selected to match them (in a 1:6 ratio) or to match the sample size of a group that received 
the same formulation in the Phase Ib study. Thus, the MN data is not available for vaccine v 
placebo groups. 
 
Comment 24 [Lesson learned]: Lines 191 Where are the authors going to mention the exciting 
preliminary results just announced for the maternal vaccination trial using nova VAX vaccine? 
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 It may be appropriate to mention this here using proper soft and reserved language (beware of 
company-spin).   
Referring to: Considerations for the future include selection of an older study population at 
higher risk of RSV infection. 
Response: In accordance with the PATH vaccine snapshot we have considered the Novavax 
vaccine candidate for maternal immunization and older adults as separate candidates. Therefore 
we have decided to mention the results for the maternal vaccine in the section on particle-based 
vaccines and not together with this vaccine failure. The main aim of the section on the vaccine 
graveyard is to distil lessons learned from large late-phase RSV vaccine trial failures. 
 
Comment 25 [Vaccine antigens]: Lines 201-203 Shouldn't the authors simply state that the 
energy of activation allowing pre-EF to change into post F is quite small, thus allowing 
"Spontaneous" conversion from pre-F to post F.   
Referring to: There is no consensus on the trigger for the pre-F to post-F conformational change 
making it difficult to ensure a wild-type F vaccine antigen maintains a pre-F conformation, but 
stabilizing mutations have been identified that can preserve the pre-F-specific epitopes(41,43). 
Response: We are not aware that the energy of activation is “quite small.” We are left the 
statement as is which states that there is not yet consensus on a trigger for RSV F protein. A 
proposed mechanism that has been published is a reduction in buffer molarity 
(Chaiwatpongsakorn, J Virol 2011). Other cellular receptors implicated in this triggering include 
TLR4 (Haynes et al, 2001), nucelolin (Tayyari et al, 2011), and ICAM-1 (Behera et al, 2001). 
Thus, ultimatey there is no consensus as published in a review on the “Structure and function of 
RSV surface glycoproteins” (McLellan et al, Curr Top Microbiol Immunol, 2014).  However we 
have consulted coauthors and rephrased the sentence to reflect this uncertainty. 
Revised text: It remains unclear as to whether there is a trigger for the pre-F to post-F 
conformational change, but it does occurs spontaneously, making it difficult to ensure a wild-
type F vaccine antigen maintains a pre-F conformation. However, stabilizing mutations have 
been identified that can preserve the pre-F-specific epitopes(53,55). 
 
Comment 26 [Vaccine antigens]:  Lines 205 Is it certain that these stabilizing mutations do not 
affect the conformation of the antibody binding sites?  Is this still an open question?  This 
reviewer does not know the answer to this but some of the authors probably do, and it would be 
appropriate to insert a simple sentence here describing the answer. 
Referring to: There is no consensus on the trigger for the pre-F to post-F conformational change 
making it difficult to ensure a wild-type F vaccine antigen maintains a pre-F conformation, but 
stabilizing mutations have been identified that can preserve the pre-F-specific epitopes(41,43). 
Response: We have consulted co-authors and added a sentence as the reviewer suggests. 
Revised text: The antigenicity of some stabilized pre-F constructs has not been rigorously 
investigated, and it remains an open question as to whether certain stabilizing mutations affect 
the conformation of antibody binding sites 
 
Comment 27 [Vaccine antigens]:  Lines 231-233 This reviewer was expecting a brief discussion 
of the relevance of ADCC to RSV prevention, as well as the evidence or lack of evidence that T 
cell responses are important. 
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Referring to: The SH protein may be important for induction of antibody dependent cell-
mediated cytotoxicity (ADCC), whereas non-membrane proteins are especially important to 
induce a robust T cell response(46) 
Response: A more detailed discussion of ADCC and T cell immunity are unfortunately beyond 
the scope of this manuscript. This section focuses on vaccine antigens that are used in candidates 
in clinical developments. We only briefly highlight there relevance for different immune 
responses but do not provide an in depth discussion of the evidence and lack of evidence of 
importance of these immune responses in this section. In the section on immunologic endpoints 
we do briefly discuss the importance of T cell immunity as a marker for protection from clinical 
disease. We hope the reviewer understands these limitations. 
 
Comment 28 [Target populations]:  Lines 253 The authors need to mention at least one of the 
major limitations of maternal vaccination strategy to protect newborn infants:  namely, that the 
elimination half-life of transplacental antibodies is naturally short, thus limiting the duration of 
protection even if passive antibody is transmitted to the infant in sufficient quantities.   
Referring to: Passive transfer of antibodies to infants has been shown to be protective against 
severe RSV infection through the administration of high-titer polyclonal and monoclonal 
antibodies (RSV-IVIG and palivizumab) (26,27). 
Response: We agree that we did not sufficiently highlight the limitations and have added this 
limitation. 
Revised text: The duration of protection of maternal vaccination is defined by the antibody half-
life. 
 
Comment 29 [Target populations]: Lines 263 The authors need to define for the readers what the 
Word preterm means. 
Referring to: Globally 10% of children are born preterm(62). 
Response: We agree with this suggestion to clarify definition of preterm for the data from the 
systematic review we are referring to. However, in this systematic review, although there was a 
general consensus across the studies on a definition of less than 37 complete weeks of gestational 
age (75/92), some studies did not report a definition (14/92) and some had a different definition 
(3/92). Therefore, it would not be accurate to list a definition as different definitions were 
included in this systematic review. 
Revised text: No change 
 
Comment 30 [Target populations]: This review would be improved if specifics were given with 
respect to relative amounts of antibody transferred at different gestational age is. References do 
exist for this data.  If preterm means less then 37 weeks, what percent of naturally transferred 
term antibody is present in these infants?   
Response: We understand that this additional level of detail is interesting, however we also feel 
that it is beyond the scope of this review. We mention that the majority of IgG transfer occurs 
before 32 weeks gestational age to give an indication of the effect of preterm birth on the 
efficacy of maternal vaccination. Further detail goes beyond the scope of this manuscript. We 
hope the reviewer finds this acceptable. 
 
Comment 31 [Target populations]: Lines 266 This reviewer believes that the reason that the 
premature infants do not receive passive antibody from mother is not because they are born 
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prematurely and therefore their umbilical cords are severed (thus cutting off flow).  Rather it is 
because the maturation of the placenta does not occur to allow transfer of antibodies prior to 
being near-term.  The wording here implies the different mechanism.  And the concept is 
important with respect to the statements regarding improved efficacy of transfer if maternal 
vaccination occurs early or late within gestation. 
Lines 268-271 See my previous comment. 
Referring to: Thus, a maternal vaccination strategy may not be sufficient to protect the high-risk 
preterm population if administered during the third trimester of pregnancy. Tetanus diphtheria 
acellular pertussis (Tdap) immunization in the second trimester is associated with higher 
antibody titers by time of birth as compared to third trimester immunization(64). A strategy of 
earlier vaccination could be considered for maternal RSV immunization to maximize protection 
to preterm infants. 
Response: There is limited data on gestational age-related antibody transfer, the most relevant 
information is from Malek (Am J Reprod Immunol, 1996). To our knowledge, it has been shown 
that prolonged maternofetal transfer cumulatively results in higher transferred IgG than exposure 
at maximum transfer efficiency which occurs at 32-33 weeks gestation age (Eberhardt, CID 
2016). We are not familiar with the statement above, that transfer of antibodies is “not allowed 
prior to being near-term. IgG transfer, although limited, is known to begin as early as 13 weeks 
gestational age, with transfer increasing in a linear fashion as pregnancy progresses (Palmeira et 
al, Clin Dev Immunol 2012). Regardless, the statement as now written does not indicate which 
mechanism underlies higher antibody titers associated with second trimester vaccination in 
comparison with third trimester vaccination. We have therefore decided to keep this section as is 
and hope the reviewer agrees. If this is not acceptable please let us know how this should be 
changed. 
 
Comment 32 [Target populations]: Lines 278-286 This entire paragraph would greatly benefit 
from the addition of a perspective of monoclonal antibody administration to infants' afterbirth, 
Referring to: A combined strategy that utilizes maternal vaccination to protect young infants 
followed by pediatric vaccination may be effective to prevent severe RSV infection in young 
children. This strategy is estimated to avert at least twice as many admissions per 100 births and 
four times as many in-hospital deaths per 1000 births than maternal vaccination alone(66). A 
combined strategy will be particularly relevant to prevent morbidity and mortality in children 
with comorbidities who are at risk of severe RSV disease at older ages (67,68). A similar 
maternal and pediatric combined passive and active immunization strategy is currently employed 
for pertussis and influenza vaccination(65).  
Response: We agree with the reviewer. We are trying to highlight a combination strategy in 
which young infants are protected via passive immunization (through maternal immunization or 
administration of mAbs) followed by pediatric active immunization. We have clarified this so 
that mAb administration after birth is equally well represented. 
Revised text: A combined strategy that utilizes passive immunization to protect young infants, 
via maternal vaccination or mAbs, followed by pediatric active immunization may be effective to 
prevent severe RSV infection in young children(78). 
 
Comment 33 [Target populations]: The extended half-life allowable by FC antibody alterations is 
a major potential improvement and needs appropriate coverage in this review.  I have not seen it 
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discussed in this review yet.  Information on these clinical trials which are ongoing, can be found 
in a few peer-reviewed publications, and clintrials.gov website. 
Response: We discuss FC alterations to extend antibody half-life in the section about MEDI-
8897 as this is mAb candidate with the YTE technology. We agree on the importance of this 
technology and have therefore also added it earlier in the manuscript when we discuss the 
limitations the duration of protection due to antibody half-life in passive vaccination. 
Revised text: The duration of protection of maternal vaccination is defined by the antibody half-
life. Administration of mAbs is an alternative form of passive vaccination that can circumvent 
this hurdle due to extended antibody half-life through Fc alterations(68). 
 
Comment 34 [Immunologic endpoints]: Lines 317 The authors need to mention the well-defined 
serologic correlate of protection which has been repeatedly defined in phase 3 clinical trials in 
infants using both polyclonal and monoclonal antibodies.  The actual level of protection in micro 
neutralization units needs to be mentioned in this review (immune experienced adults).  This is a 
unique and important feature of RSV which can inform future vaccine development greatly. 
Referring to: The mechanisms of protection may differ according to the type of vaccine, and 
therefore, many different immunologic assays are employed in clinical trials. 
Response: To our knowledge there is no well-defined serologic correlate of protection, nor is 
there an “actual level” of protection in micro neutralization units. All authors on this manuscript 
have read and approved this section which argues that there is no definitive immunologic 
correlate of protection and that there is no consensus in the field in this regard. If there is specific 
evidence on vaccine-specific correlates of protection, we will gladly add this to our manuscript. 
Comment 33 [Immunologic endpoints]: Lines 341 See my comment above.  Is it really 
"elusive"? 
Response: Please see response to comment 32 above. 
 
Comment 35 [Immunologic endpoints]: 357 some of them have been shown to be safe, but 
others have definitely NOT been shown to be safe.  The authors need to modify this statement. 
Accordingly.  This reviewer believes they did not show vaccine enhanced disease, but that is a 
separate issue than safety. 
Replication deficient vectors, engineered to induce CD8 T cell 
356 responses expressing RSV antigens intracellularly, are considered more similar to 
357 live-attenuated virus vaccines which have been shown to be safe in this population. 
Referring to: Replication deficient vectors, engineered to induce CD8 T cell responses 
expressing RSV antigens intracellularly, are considered more similar to live-attenuated virus 
vaccines which have been shown to be safe in this population. 
Response: We agree that it has been shown that these are shown not to be associated in ERD. We 
have rephrased the wording as the reviewer suggests. 
Revised text: Replication deficient vectors, engineered to induce CD8 T cell responses 
expressing RSV antigens intracellularly, are considered more similar to live-attenuated virus 
vaccines which have been shown not to cause ERD in this population. 
 
Comment 36 [Particle-based]: 393-396 Authors need to verify that this information is publicly 
releasable, or has already been released which necessitates a reference being placed here.   
Referring to: Assays of serum virus neutralization, RSV F-specific antibodies, palivizumab-
competing antibodies and F-specific IgA indicated some immunogenicity, but the results did not 
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reach the threshold set for continuation to viral challenge and the studies were suspended in 2017 
(Openshaw and Chiu, personal communication). 
Response: We have obtained written consent from the two authors mentioned to release this 
information. It is otherwise not yet available in the public domain. 
 
Comment 37 [Vector-based]: 410-413 This statement is confusing. How does a vaccine - 
induction of a humoral response correct the impaired T cell immunity supposedly encountered in 
the elderly?  Do the authors mean "cell mediated response rather than "humoral response"? 
Referring to: Given that severe disease in the older adult population is thought to be mediated by 
immunosenescence characterized by impaired T cell response, this vaccine candidate, which 
induces a humoral response, may be a promising intervention for the older adult population(81). 
Response: In this case we do not mean humoral response. We expect a vaccine candidate not to 
be able to induce an adequate T-cell response but to be able to induce an adequate humoral 
response. For this reason, we expect this candidate to be able to induce a strong and effective 
immune response. However, we agree that the wording was confusing because we also wrote 
that severe RSV disease was mediated by impaired T-cell response. For this reason, we have 
rephrased this sentence for clarity. 
Revised text: In the older adult population, immunosenescence may be characterized by impaired 
T cell responses to RSV(97,98). Thus, this vaccine candidate which induces a humoral response 
may be a promising intervention in this population. 
 
Comment 38 [Subunit]: 461-463 Can this statement be updated with the reference now? What 
about a presentation at a publicly disclosed meeting? 
Referring to: Phase I results on safety and immunogenicity in the older adult population will 
soon be published from an investigator-initiated study. 
Response: Unfortunately these results are not yet in the public domain so we cannot update this 
with a reference. However, we have reworded the sentence because we agree that it can 
otherwise not stand without a reference. 
Revised text: Phase I results on safety and immunogenicity in the older adult population have 
been released and are expected to be published from this investigator-initiated study. 
 
Comment 39 [mAbs]: 509 The authors should briefly mention the effect of this YTE mutation 
on the functionality of the antibody with respect to antibody dependent Cellular cytotoxicity and 
other signaling pathways.   
Referring to: Using the YTE technology for extending antibody half-life, the three-fold increase 
in half-life of MEDI8897(91) compared to palivizumab offers the possibility of passive 
protection for all infants for an entire season through a single intramuscular injection. 
Response: We have added this statement as the reviewers suggest with an appropriate citation. 
Revised text: Using the YTE technology which extends antibody half-life as well as modulates 
ADCC(111), the three-fold increase in half-life of MEDI8897(112) compared to palivizumab 
offers the possibility of passive protection for all infants for an entire season through a single 
intramuscular injection. 
 
Comment 40 [mAbs]: 516 This section needs to be expanded to review the clinical development 
progress of this antibody as mentioned by Clintrials.gov 
Section on monoclonal antibodies 
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Referring to: Representatives of the pharmaceutical company have indicated that they expect 
vaccine-like pricing of MEDI8897. Given the increased potency, the extended half-life, and the 
required dose, it is expected that the cost to protect an infant during the RSV season can be kept 
relatively low(92). 
Response: As far as we know the section on mAbs is up-to-date with clinicaltrials.gov. Please 
also see the mAbs in clinical development on the PATH snapshot we we used to define the scope 
of this manuscript. Please let us know if additional information is needed for the mAb paragraph. 
 
Comment 41 [mAbs]: 517 The authors should also mention the major effect of improved 
manufacturing techniques of monoclonal antibodies which have been developed over the past 
decade which allows significantly less expensive production.  
Referring to: Passive vaccination with an extended half-life antibody offers an approach to 
protecting infants that is safe and may be reasonably priced. Representatives of the 
pharmaceutical company have indicated that they expect vaccine-like pricing of MEDI8897. 
Given the increased potency, the extended half-life, and the required dose, it is expected that the 
cost to protect an infant during the RSV season can be kept relatively low(68). 
Response: Although we agree with the reviewer, we felt that further analysis cost-related issues 
was beyond the scope of this review. 
 
Comment 42 [References]: 1.there needs to be a mention of Galvani (sr. author) PNAS paper  
Response: Please see response to comment 9 above. 
 
Comment 43 [Table 2]: Overview of vaccines and MAbs by target population: 
1.where are the MAbs mentioned? 
Response: mAbs is the last category in the table. 
 
Comment 44 [Table 3]: Expected immune response and precious successes for vaccine….1.do 
you need to mention RGN-2222? (MAb)? 
Response: This table only contains mAbs that are in clinical development according to the PATH 
vaccine snapshot, which is why we have not included REGN-2222. 
 
Comment 45 [Figure 1]: RSV global burden of disease in children: key facts and figures 
This figure needs a lot of work and a greatly expanded footnote to add more detail to the various 
statements made.  For example: 
 
Comment 46 [Figure 1]: 1. is the 3.2 million hospitalization number from developed countries? 
If so, how does this fit with the fact that there are only 33.1 million RSV LRT eyes worldwide? 
 A 10% hospitalization rate for RSP L RTI is quite hi depending on what age range are being 
evaluated.  Likewise, the blue circle needs greater granularity also.  I.e., which age range are we 
talking about? 
Response: This concerns the hospitalization worldwide, we have clarified this in the legend. 
 
Comment 47 [Figure 1]: 2. authors should explain the numerator and denominator of the 15.9 
divided by 1000 new units per year. They also need to define the other rates mentioned in the 
green circles. 
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Response: 15.9 is the rate of neonates per year and this is also written inside of the green circle. 
We have added a clarifying sentence in the legend 
Revised text: The hospital admission rate of 15.9 hospital admissions per 1000 neonates per year 
is in developing countries. 
The RSV ALRI hospitalization 63.9 among premature infants <1 year is reported per 1000 
children per year globally. 
 
Comment 48 [Figure 1]: 3.  might it be better to have a separate set of circles for infants in the 
developed world and another set for infants in the developing world?  Might it be better to also 
include adults in this figure?  As I understand, the review is not focused solely on children. 
Response: We have decided to limit this figure to include only children. All rates have been 
specified inside of the green circles. We have also clarified in the legend which figures are global 
and which are for the developing world. 
 
Comment 49 [Figure 2]: Overview of Vaccine candidates…(heading) 
1. This figure seems to be limited to those that are in clinical trials rather than those that are 
in clinical development.  There are a lot more of these in clinical development.  I suggest 
renaming the title to show that you are listing only those Advanced into clinical trials 
Response: Figure 2, just as table 1 and table 2, and the entire manuscript focuses on vaccine 
candidates and mAbs for RSV in clinical trials only, not in preclinical testing. The only thing that 
has been added to this figure is candidates that are no longer in development since the review we 
published in the Lancet Respiratory Medicine. Nevertheless, we have changed the heading for 
this figure so that it is clearer what the scope of the figure entails. 
Revised text: Figure 2: Overview of vaccine candidates and monoclonal antibodies in clinical 
trials per preventive approach including candidates for which development was recently halted 
 
Comment 50 [Figure 2]: Monoclonal: 
The regeneron molecule needs to be placed here. Also, the polyclonal product respimmune.   
Also, palivizumab needs to be placed here. 
Response: We agree that REGN-2222 needs to be added and have done so. However 
respimmune and palivizumab fall outside the scope of this figure as they are no longer in clinical 
development and we have therefore not added them. 
Revised text: Addition of REGN-2222 
 
Comment 51 [Figure 2]: Vector-Based: 
The Sendai virus backbone based vaccines need to be mentioned too since other phase ones have 
been mentioned 
Response: The vaccine candidate with a Sendai backbone, we believe you are referring to 
(PMID: 28250126) is not yet in clinical development and has therefore not been included in this 
figure. 
 
Comment 52 [Figure 2]:I believe there are some G - protein-based subunits vaccines.  If so, they 
should be mentioned.  The black label F- protein stands out, but there is no balanced label for 
SH.   
Response: Currently there are no G protein-based subunit vaccines in clinical development, 
which is why we have not included them in this figure. Please refer to the most recent PATH 
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vaccine snapshot for an overview of vaccines and mAbs for RSV in clinical development. We 
hope we have addressed the reviewer’s concerns adequately. 
 
Comment 53 [Figure 2]:I don't understand what the label inside the purple circle means. It looks 
like this label needs to be removed. 
Referring to: Ad26/5; ChAd155, MVA 
Response: The label inside the graphic represent vector-based vaccines are the vectors that are 
used for these vector-based vaccines. The idea was to give an overview of all vectors employed 
for this preventive approach. However, we agree that this is more confusing than it is helpful and 
have removed this label as the reviewer suggests. 
 
Comment 54 [Figure 2]:It also looks like the label inside the blue circle needs to be removed 
(there are other live attenuated chimeric's other than BCG - based.   
Referring to: RSV/BCG 
Response: At this moment, there are no other chimeric vaccines in clinical development than the 
BCG vaccine. However, we agree that the figure is clearer with this removed and have done so. 
Please see response to comment 51 above. 
 
Comment 55 [Figure 2]: Subunit: Colors need to be altered to allow better visualization. This is 
especially true of the lavender and peach colored approaches. 
Response: We have changed the color to a darker color to allow for better visualization as the 
reviewer suggests. 
 
Comment 56 [Figure 2]: Particle Based: (RSV F nanoparticle) 
If this is the novaVAX vaccine, the company needs to be identified within the graphic. (in 
harmony with the other parts of this graphic. 
Response: We understand the reviewer’s suggestion. However, we have not mentioned the 
company names anywhere in the manuscript besides Table 1 under the column 
“company/sponsor.” Toa void any commercial biases, we have decided to not use any 
pharmaceutical names but instead the index name of the vaccine candidate or mAb. Sometimes 
this includes an abbreviation of the company name but never the entire company name. For 
consistency, we have not added in “Novavax” in this figure. 
 
Comment 57 [Figure 2]: Particle-Based: (SynGEM) 
Since this particle based vaccine has been halted, shouldn't it be in gray? 
Response: We understand your comment. Only vaccine candidates or mAbs that were previously 
halted have been made gray. All vaccine candidates and mAbs considered in clinical 
development according to the PATH snapshot are still in color. Likewise, the GSK adenovirus 
26 preF vaccine has PhII has been halted and it is unclear whether development will continue. 
For SynGEM, this is the first publication, which will contain information in the public domain 
that mentions development being halted. For consistency, we have kept all 19 candidates in 
development according to the PATH snapshot in color in this figure and older candidates in grey. 
Please let us know if you feel a change is necessary. 
 





Comment 1 [General]: This is a well-written review of the RSV vaccine candidates and Mabs 
currently in clinical development. In view of the considerable global burden of RSV and the 
urgent need for efficacious vaccines for the populations most severely affected by RSV, this 
review is very timely. In addition, with so many vaccine candidates in clinical development, and 
many more in pre-clinical stages, this provides an excellent reference. 
Response: We thank the reviewer for recognizing the importance of this manuscript to the field 




Comment 2 [Lessons learned]: Line 178: What was the TLR4 agonist adjuvant and is this an 
optimal adjuvant based on pre-clinical studies, or could stronger ones be used that might promote 
higher levels of immunity?  
Referring to: MEDI-7510 was a subunit vaccine using soluble (unaggregated) postfusion (post-F) 
conformation of the F protein with a TLR4 agonist adjuvant that showed safety and 
immunogenicity with elevated B and T cell responses in the vaccine group compared to the 
placebo group in phase I clinical trials(39). 
Response: The adjuvant is a glucopyranosyl lipid adjuvant (GLA) which was administered in a 
squalene-based 2% emulsion (GLA-SE). Phase I clinical testing provided support for inclusion 
of the adjuvant in the vaccine candidate (Falloon et al, Vaccine 2016 and Falloon et al Clin 
Vaccine Immunol 2017). In the first-in-man trial the vaccine was tested with the adjuvant and 
unadjuvanted, no other adjuvants were tested. The adjuvant was found to increase both humoral 
and cellular immune responses. Thus, given available evidence the best possible adjuvant was 
selected to continue into phase II clinical trials. We hope this answers the reviewer’s question 
sufficiently. 
 
Comment 3 [Lessons learned]: On line 179 the authors refer to induction of B and T cell 
responses in the group vaccinated with MEDI-7510; it is important to provide information about 
induction of VN antibodies, which are correlated to protection. Were they measured and if so, 
what were the levels? 
Referring to: MEDI-7510 was a subunit vaccine using soluble (unaggregated) postfusion (post-F) 
conformation of the F protein with a TLR4 agonist adjuvant that showed safety and 
immunogenicity with elevated B and T cell responses in the vaccine group compared to the 
placebo group in phase I clinical trials(39). 
Response: We agree that virus neutralization titers are most informative regarding the ability of 
the candidate to induce an effective immune response. VN titers were not reported for the IIb 
trial for vaccine v placebo groups. We have made this explicit in the manuscript. 
Revised text: (50). Microneutralization, PCA and cell-mediated immunogenicity responses were 
only reported in subset analyses and therefore there is no data on microneutralization activity in 
the vaccine group versus the placebo group for this trial. 
 
Comment 4 [Lesson learned]: Line 191: An alternative might be to increase the study population.  
Referring to: Considerations for the future include selection of an older study population at 
higher risk of RSV infection 
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Response: Increasing the study population would have been necessary if this trial failure was due 
to an underpowered study. However, based on available knowledge from phase II the phase III 
trial was adequately powered. We mention extending enrolment by an additional RSV season 
since the pharmaceutical company has attributed the failure to a low attack rate and performing a 
trial over several seasons would have allowed for a more even distribution of attack rates from 
season to season, especially for a pivotal phase III trial. We hope this addresses the question. 
 
Comment 5 [Immunologic endpoints]: Line 322: Would a ratio of fold-increase in RSV-binding 
antibodies to RSV neutralizing antibodies of 1 not be as effective?  
Referring to: A measure of functional antibody response can be elucidated by the ratio of fold-
increase in RSV-binding antibodies to fold-increase in RSV-neutralizing antibodies (ELISA-to-
neutralization response ratio). 
Response: This statement described total antibodies to functional antibodies. The higher the 
amount of functional antibodies in proportion to total antibodies (when this ratio is <1), the 
greater the neutralizing activity. However, there is no consensus on this measure nor is there an 
exact cut off for optimal neutralizing activity. However, the lower the ratio the more effective so 
the answer is yes, a ratio of 1 would not be as effective. 
 
Comment 6 [Vector-based]: Lines 406-413: This section should be deleted. The VXA-RSV-f is 
described under "five vector-based vaccines in clinical development" (line 399), but this vaccine 
candidate is not in clinical trials and thus does not fit within this manuscript - if the authors want 
to include RSV vaccines in pre-clinical development, there are many other promising candidates 
that should be discussed. More importantly, the information on results from the pre-clinical 
studies on VXA-RSV-f is not useful at all, as "enhanced IgA in the upper airways" does not 
mean anything unless supported by protection data. Furthermore, no reference is provided to 
support this statement. Reference 81 refers to a 2013 study on RSV viral shedding in adults, 
totally unrelated to this vaccine candidate.   
Referring to: The second vector-based vaccine candidate, VXA-RSV-f, uses an innovative 
platform with an adenovirus 5 based oral tablet delivery platform that is stable at room 
temperature. The results from preclinical studies show that mucosal immunization with the oral 
vaccine candidate enhanced mucosal IgA in the upper airways. Given that severe disease in the 
older adult population is thought to be mediated by immunosenescence characterized by 
impaired T cell response, this vaccine candidate, which induces a humoral response, may be a 
promising intervention for the older adult population(81). 
Response: The Vaxart RSV vaccine candidate has entered phase I clinical trials in June 2016, 
please refer to the PATH Vaccine snapshot as well as clinicaltrials.gov (NCT02830932). In the 
manuscript text, we have focused only on candidates in clinical trials including this candidate. 
Unfortunately, since phase I is recruiting we can only mention data from preclinical testing. The 
reference to the 2013 paper was included in reference to immunosenescence mediated by 
impaired T cell function and was not supposed to be related to this vaccine candidate. We agree 
with the reviewer that references need to be added into this section regarding the vaccine 
candidate in question and have done so. The enhanced mucosal IgA in the upper airways was 
presented at the 2017 RSV vaccines for the World conference but is as of yet unpublished in a 
peer-reviewed journal. Therefore, we have decided to cite the phase I data from the influenza 
vaccine candidate using the same oral platform and vector. Furthermore, we have included the 
preclinical data which are mentioned in a press release on the company website. 
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Revised text: Using the same oral adenovirus vaccine delivery platform, a phase I trial for 
influenza has been conducted, which showed a neutralizing antibody responses against influenza 
in the vaccine group and no interference of pre-existing vector immunity(96). Preclinical studies 
for the RSV vaccine candidate in the cotton rat model showed an increase in anti-F antibodies 
and protection against RSV challenge(97). 
 
Comment 7 [Vector-based]: Line 415: The phrase "The candidate uses pre-F antigen" is unclear; 
the authors likely mean: "In this vaccine candidate, pre-F antigen is expressed in… etc".  
Referring to: The candidate uses pre-F antigen expressed in the human adenovirus strain 26, a 
vector with a favorable safety profile when used for other infectious diseases(82,83). 
Response: We have revised this according to reviewer’s comments and agree that this is clearer. 
Revised text: In this candidate pre-F antigen is expressed in the human adenovirus strain 26, a 
vector with a favorable safety profile when used for other infectious diseases(100,101). 
 
Comment 8 [Live-attenuated]: Lines 469-474: There is ample evidence that live-attenuated 
vaccines are often inhibited by maternal/ circulating antibodies. What is the evidence that live-
attenuated RSV vaccines generate a strong enough immune response in the presence of maternal 
antibodies (how robust were those responses), and if so, why would such a vaccine then be 
expected to be inhibited by the presence of RSV-specific circulating antibodies in older adults?  
Referring to: Another benefit of live-attenuated vaccines in the pediatric population is their 
ability to generate an immune response despite the presence of maternally-acquired 
antibodies, and to elicit a more broad antibody and cellular response(89). Live-attenuated 
vaccines are likely limited to the pediatric population under two years of age, as pre-
existing immunity in older populations might not permit sufficient replication to generate 
protective immune responses. 
Response: We agree that this is not accurately written as there is evidence of interference due to 
pre-existing immunity for live-attenuated vaccines. We have rephrased this sentence to clarify 
that there is empirical evidence for live-attenuated RSV vaccines that they are able to replicate in 
the upper respiratory tract of young infants despite pre-existing maternally acquired antibodies. 
This is indeed not true of ALL live-attenuated vaccines in ALL populations. We hope the 
reviewer will find this modification acceptable. The evidence for this statement comes from two 
RSV live-attenuated vaccine candidates which have been tested in 1-2 month old infants in 
which viral peak titers in nasal wash specimens demonstrated equal or higher viral replication 
when compared to seronegative 6-24 month children (presumed to have no residual maternally-
acquired antibodies). 
Revised text: Another benefit of live-attenuated vaccines against RSV in young infants is their 
ability to replicate in the respiratory tract despite the presence of maternally-acquired antibodies, 
and to elicit a broad humoral and cellular response(108). 
 
Comment 9 [Live-attenuated]: Lines 480-493: Of the five live-attenuated vaccine candidates in 
Phase I clinical trials, the results for only one, MEDI <DELTA>M2-2, are provided. What is the 
developmental stage of the other four and what are they?  
Referring to: Five live-attenuated vaccine candidates in phase I clinical trials are being developed 
in partnership with the National Institutes of Health (NIH).  Live-attenuated vaccines face the 
challenge of achieving sufficient attenuation to be safe while remaining immunogenic enough to 
induce a protective immune response, but improved understanding of the RSV viral genome has 
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informed the development of new vaccine candidates that may overcome this challenge. Two 
main modifications to the RSV genome have been engineered through reverse genetics: the 
ΔM2-2 deletion which attenuates viral replication and upregulates antigen expression(32) as well 
as the ΔNS2 deletion which reduces viral suppression of host interferon thereby boosting the 
innate immune response. RSV MEDI ΔM2-2 strongly reduced viral replication while inducing a 
strong primary serum neutralizing antibody as well as potent anamnestic response in RSV-
seronegative infants and children(32). Further results from phase I clinical trials with live-
attenuated vaccines are expected. 
Response: The other four candidates are in Phase I clinical trials. We have not provided the 
results as they are not yet available in the public domain, this is also why we write “further 
results from phase I clinical trials with live attenuate vaccines are expected.” We have rephrased 
this for clarity. 
Revised text: Further results from phase I clinical trials with the other live-attenuated vaccine 
candidates are expected. 
 
Comment 10 [Discussion]: Line 573: Typo: plans  
Referring to: We attempted to collect data regarding expected plan for access to a preventive 
intervention in LMICs and expected pricing for all vaccine candidates, however this information 
was not publicly available. 
Response: We have changed this as suggested by the reviewer. 
Revised text: We attempted to collect data regarding expected plans for access to a preventive 
intervention in LMICs and expected pricing for all vaccine candidates, however this information 
is not publicly available. 
 
Comment 11 [Table 1]: Page 32: Typo: ectodomain 
Referring to: SHe: small hydrophobic protein ectodomiain 
Response: Thank you for the observant correction. We have fixed the typo. 
Revised text: SHe: small hydrophobic protein ectodomain 
 
Comment 12 [Figure 1]: Page 36, Fig 1: Add ALRI explanation to legend. 
Referring to: all ALRI mortality 
Response: Instead of adding ALRI to the legend we have decided to consistently use LRTI 
throughout the figure. 
Revised text: all LRTI mortality 
 
Comment 13 [General]: Supplementary Table 1: only the first column is useful, the rest contains 
no heading or information, so can be deleted. Typo: Adjuvants 
Response: We agree that the rest of the template contains no useful information. However, we 
have added the column headings so that it is clear which template was used for data collection as 
this is key to the systematic collection of data for this manuscript. We have also fixed the typo 
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